

Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) Checklist Version 3:2023

For Clinical and Public Health Laboratories

Introduction

Medical laboratories play an essential role in determining clinical decisions and providing clinicians with information that assists in the prevention, diagnosis, treatment, and management of diseases. However, inadequate investment has meant that many medical laboratories in Africa lack the necessary infrastructure, equipment, and resources to provide an effective and quality service. Although the last decade has seen significant strides in the strengthening of laboratory systems in Africa, challenges remain across most countries at all tiers of their systems. Therefore, the strengthening of laboratory systems and services remains a priority. The establishment of a process by which laboratories can establish and monitor management systems towards the achievement of accreditation to international standards remains an invaluable tool for countries to improve the quality of laboratory services in a stepwise and sustainable manner.

In accordance with World Health Organization (WHO) core functions of setting standards and building institutional capacity, WHO Regional Office for Africa (AFRO), in collaboration with the African Society for Laboratory Medicine (ASLM), the United States Centers for Disease Control and Prevention (CDC) and host countries established the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) to strengthen the laboratory management systems of its Member States. SLIPTA is a framework for improving the quality of medical laboratories in developing countries to achieve the requirements of the International Standards Organization (ISO) 15189 standard. It is a process that enables laboratories to develop and document their ability to detect, identify, and promptly report all diseases of public health significance that may be present in clinical samples.

This initiative was spearheaded by several critical resolutions, including WHO Resolution AFR/RC58/R2 on Public Health Laboratory Strengthening, adopted by the Member States during the 58th session of the Regional Committee in September 2008 in Yaoundé, Cameroon, and the 2003 Maputo Declaration to strengthen laboratory systems. This quality improvement process towards accreditation further provides a learning opportunity and pathway for continuous quality improvement, a mechanism for identifying resource and training needs, a measure of progress, and a link to the WHO's Laboratory Networks and Services team. Clinical, public health, and reference laboratories participating in the SLIPTA programme are supported in the process of establishing or strengthening their management systems to compliance with international standards in a stepwise manner, that recognises their progress through audits and the awarding of certificates of recognition. This quality improvement, a mechanism for identifying resource and training needs, better commitment of management and personnel that ensure quality diagnostic service in line with WHO AFRO complete healthcare services.

This checklist was developed as a framework and guide for laboratories on all the necessary elements to set up a functioning laboratory management system that meets international standards. This third edition has been updated through an expert review process to align with the new ISO 15189:2022 standard. This checklist is to be used in parallel with the SLIPTA Implementation Guide, which provides further guidance on requirements and implementation considerations.

<u>Scope</u>

This checklist specifies requirements for quality and compliance aimed to develop and improve laboratory services to established national standards. The elements of this checklist are based on ISO standard 15189:2022 (E) and, to a lesser extent, the Clinical & Laboratory Standards Institute (CLSI) guideline QMS01-A4, Laboratory Management System: A Model for Laboratory Services; Approved Guideline – Fourth Edition.

This document is applicable to medical laboratories in developing their management systems and assessing their compliance.

This document is also applicable to point-of-care testing (POCT).

Recognition is provided using a five-star, tiered approach, based on a bi-annual, on-site audit of laboratory operating procedures, practices, and performance. The audit checklist score will correspond to the number of stars awarded to a laboratory in the following manner:

No Stars	1 Star	2 Stars	3 Stars	4 Stars	5 Stars
(0 – 205 pts)	(206 – 240 pts)	(241 – 277 pts)	(278 – 314 pts)	(315 – 352 pts)	(353 – 367 pts)
< 55%	55 – 64%	65 – 74%	75 – 84%	85 – 94%	≥95%

<u>Purpose</u>

The intended purpose of the SLIPTA Checklist is to evaluate and verify the establishment, implementation and improvement of the quality management system in medical laboratories. This checklist shall be completed by a trained and certified SLIPTA Auditor and is for recognition purposes based on the SLIPTA star levels. The SLIPTA certificate will not replace accreditation or certification.

Instructions for use

The SLIPTA checklist promotes the adoption of a process approach when developing, implementing and improving the effectiveness of a management system, with the objective of meeting customer expectations and providing laboratory testing services.

When this checklist is used as a soft copy, it can be completed as a form by typing in the grey blocks.

The guidance given as "*Note*" in each question describes concepts, examples and methods that can be considered by the organisations when the laboratory is establishing, implementing and maintaining a management system.

An organisation can incorporate guidance from the "*Note*" in each question, wholly or in part, into its management system.

Parts of the Audit

This Laboratory audit checklist consists of three parts:

Part I: Laboratory Profile

Part II: Laboratory Audits

Evaluation of Laboratory operating procedures, practices, and tables for reporting performance

Part III: Summary of Audit Findings

Summary of findings of the SLIPTA audit and action planning worksheet

Part I: Laboratory Profile

LABORATORY PR	OFILE											
Date of this Audit:	:						Date o	of La	ast Audit:			
Prior Audit Status ASLM official aud	it	Not Audi		0 Stars	1	Star	2 St	ars	3 Sta	rs	4 Stars	5 Stars
Name(s) and Affili	ation(s)	of Auditor	(s):									
Laboratory Name:										Labo	oratory Num	ber:
Laboratory Addre (Country, City and	ss: J GPS c⁄	o-ordinate:	5)									
Laboratory Teleph	none:		Fax:						Email:			
Name of Laborato	ry Repr	esentative	:			Teleph Repres					Personal:	
						•		,			Work:	
Laboratory Level						Туре о	of Labo	rato	ory/Labora	atory	Affiliation	
National	Refe	rence	Pr	rovincial		Publ	lic	F	Private		Faith-Bas	ed
District	Zona	al	F	ield		Milita	ary	Re	search		Othe	-
											Please spec	ify:
Laboratory Staffin	ig Sumr	nary						<u> </u>				
Profe	ession			Number of Time	Full			A	dequate f	or fa	cility operat	ions?
Degree-holding Pro	ofessiona	al Staff				+	Ye	es	No		Insufficient D	Data
Diploma-holding Pr	ofessior	nal Staff				+	Ye	es	No		Insufficient D	Jata
Certificate-holding I	Professi	onal Staff				+	Ye	es	No		Insufficient D	Jata
Data Clerk			+			+	Ye	es	No		Insufficient D	Data
Phlebotomist			+			+	Ye	es	No		Insufficient D	Jata
Cleaner			+			+	Ye	es	No		Insufficient D	Jata
Is / Are the cleaner	(s) dedic	ated to the	laboi	ratory		Ha	s the cl	ean			ned on safety	' and
only? Yes 🗌 No [No []		waste handling? Yes 🗌 No 🗍						
Number of Driver/C	ourier/N	lessenger					Ye	es	No		Insufficient	Data
Is / Are the driver(s, the laboratory only?		er(s) / messo Yes	enge No	r(s) dedicate	ed to	Has		ə dri 'es	iver(s) bee No	en tra	ined in biosa	fety?
Other		163					Ye	es	No		Insufficient D	Jata
If the laboratory h management staff												,

Part II: Laboratory Audits

Laboratory audits are an effective means to:

- a. Determine if a laboratory is providing accurate and reliable results;
- b. Determine if the laboratory is well-managed and is adhering to good laboratory practices; and
- c. Identify areas for improvement.

Auditors must complete this SLIPTA checklist using the methods below to evaluate laboratory operations as per the checklist questions and to document audit findings (including strengths of the laboratory operations).

- **Review laboratory documents** to verify that the laboratory quality manual, policies, standard operating procedures (SOPs) and other manuals (e.g., safety manual and laboratory handbook) are complete, current, periodically reviewed and document controlled.
- Review laboratory records such as equipment maintenance records, incident reports, environmental condition logs, personnel files, internal quality control (IQC) records, external quality assessment (EQA) records, etc.
- Observe laboratory operations to ensure:
 - Laboratory testing follows written policies and procedures in pre-examination, examination and postexamination processes of laboratory testing;
 - Laboratory procedures are appropriate and current for the testing performed; and
 - Observations and nonconformities identified are adequately investigated and resolved within the defined timeframe.
- Ask open-ended questions to clarify documentation reviewed and observations made. Ask questions like, "show me how..." or "tell me about...". It is often not necessary to ask all the checklist questions verbatim. An experienced auditor can often learn to answer multiple checklist questions through open-ended questions with the laboratory staff.
- Follow a specimen through the laboratory from collection through all the laboratory processes (i.e., preexamination, examination and post-examination).
- Confirm that each test result or batch of results can be traced and verified against acceptable IQC results.
- Confirm EQA / proficiency testing results are reviewed and corrective action taken as required.
- Evaluate the quality and efficiency of supporting work areas (e.g., phlebotomy, data registration and reception, messengers, drivers, cleaners, IT, etc.).
- Interview clinicians to establish the users' perspective of the laboratory's performance.

Audit Scoring

This SLIPTA Checklist contains 12 main sections with a total of 145 questions and a possible total score of 367 points.

For each question, indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field, the auditor must provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

Each item has been awarded a point value of 2 or 3 based upon relative importance and/or complexity.

• Questions marked **(Y)** will receive the corresponding point value 2 (two) or 3 (three). All elements of a question must satisfactorily be present in order to indicate **(Y)** for a given question and thus award the corresponding points.

NOTE: Questions that include 'sub-questions' must receive all (Y) and/or (NA) responses to be marked (Y) for the overarching item.

- Items marked (P) will receive 1 (one) point for all questions.
- Items marked (N) receive 0 (zero) points.

When marking (P) or (N), notes must be written in the comments field to explain why the laboratory did not comply. Where the checklist question does not apply, indicate as (NA). The laboratory shall have documented justification for (NA).

Add the sum of all main questions marked **(NA)** and subtract that sum of **(NAs)** from the total of 367. Since denominator has changed, the star level will then be determined using % score.

Audit Score Sheet						
Section					Total possible score	
Section 1: Docume	ents and Records				22	
Section 2: Organis	ation and Leadership				26	
Section 3: Person	nel Management				34	
Section 4: Custom	er Focus				24	
Section 5: Equipm	ent Management				38	
Section 6: Assess	ments				24	
Section 7: Supplie	r and Inventory Mana	gement			27	
Section 8: Process Management					71	
Section 9: Information Management					24	
Section 10: Nonconforming Event Management					13	
Section 11: Continual Improvement					07	
Section 12: Facilities and Safety					57	
TOTAL					367	
Calculated percentage score obtained					%	
No Stars 1 Star 2 Stars 3 Stars 4 Stars (0 - 205 pts) (206 - 240 pts) (241 - 277 pts) (278 - 314 pts) (315 - 352 pts) < 55% 55 - 64% 65 - 74% 75 - 84% 85 - 94%		, , ,				

SECTION 01: DOCUMENT AND RECORDS

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field, you may also provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

	Y/P/N/	
REQUIREMENTS	NA	Comment
1.1 <u>Legal Entity</u> Does the laboratory have documentation stating its legal identity?		Score /2
Note: Documentation could be in the form of a National Act, company registration certificate, license number or practice number, official letter from the Ministry of Health or equivalent institution to indicate that it belongs to the government.		
ISO15189:2022 Clause 5.1		
1.2 Laboratory Management System Policies and		Score /3
<u>Objectives</u>		
Is there a current document (quality manual or		
equivalent) that is composed of the management system policies and objectives and has the content		
being communicated and understood by all personnel?		
Note: A document (however named) must be available that summaries the laboratory's management system, which includes policies that address all areas of the laboratory service and identifies the goals and objectives of the Laboratory Management System.		
Does the document include the following elements?		
a. Quality policy statement that includes scope of		
service, standard of service, measurable objectives		
of the laboratory management system, and		
management commitment to compliance to the implementation of the policies;		
b. Documented policies of the laboratory management		
system that meet the requirements of		
ISO15189:2022 and the requirements of the		
accreditation bodies (where relevant);		
 Description of the laboratory management system and the structure of its documentation; 		
Note: A graphical representation of the hierarchy of the documents and what each level means is required.		
 Reference to supporting procedures (e.g., SOPs), including managerial and technical procedures; 		
Note: The document number and/or document title is sufficient; a link to the relevant folders may be used for a paperless system.		
e. Description of the roles and responsibilities of the		
laboratory director (however named) and other key		
personnel responsible for ensuring compliance with the established organisational structure		
(organogram);		
Note: The laboratory management must define its key personnel.		
f. Record of review and approval of this document		
(quality manual or equivalent) by authorised		
g. Records to show that relevant sections of this		
g. Records to show that relevant sections of this document were communicated to and understood by		
the relevant personnel (internal and external		
persons).		
Note: Internal personnel is any person indicated within the organogram of the organisation.		
ISO15189:2022 Clause 5.5, Clause 8.1.1 and Clause 8.2	•	

1.3 Document and Information Control System	Score /2
Has the laboratory management established and	
implemented a document control system to control all	
documents and information from internal and external	
sources?	
Note: A document control system ensures that all documents (internal and external) are approved by authorised persons,	
current, reviewed periodically and revised as required.	
ISO15189:2022 Clause 8.3	
1.4 Document and Records	Score //
Are there records detailing all documents of the	
laboratory management system and indicating their	
editions and distribution?	
Note: Current authorised editions and their distribution are	
identified by means of a list (e.g., document register, log, or	
master index). "Edition" can be regarded as synonymous with "revision or version" number for the documents.	
ISO15189:2022 Clause 8.3	
1.5 Laboratory Management System	Score //
Documentation	
Note: The management system documents can be contained in a	
quality manual; however, if the system is computerised, all files	
bearing the objectives and policies shall be linked.	
a. Has the laboratory management established,	
documented and maintained objectives and policies	
to fulfil the requirements of ISO 15189:2022	
standards?	
b. Are these objectives and policies acknowledged and	
implemented at all levels of the laboratory?	
ISO15189:2022 Clause 8.2	
1.6 <u>Quality Document Accessibility</u>	Score /2
Are quality documents (paper based and/or electronic	
copies) easily accessible, available and written in a	
language commonly understood and communicated to	
all relevant personnel?	
Note 1: This includes external personnel.	
Note 2: All documents must be current and approved by an	
authorised person. The documents can be in any form or type of	
medium provided that the documents are readily accessible and protected from unauthorised changes and undue deterioration.	
ISO15189:2022 Clause 8.2.5	
1.7 Document Control Record	Score /3
Do all quality documents have a record to reflect when it	
was approved for use, its review and revision history, its	
version, its location and when it was discontinued?	
ISO15189:2022 Clause 8.3	
1.8 Discontinued Quality Documents	Score //
Are invalid or discontinued quality documents identified,	Scole 12
clearly marked, removed from use and one copy	
retained for reference purposes?	
Note: Obsolete controlled documents shall be dated and marked	
as obsolete. At least one copy of an obsolete controlled	
document is retained for a specified time or in accordance with	
document is retained for a specified time or in accordance with applicable specified requirements.	
document is retained for a specified time or in accordance with applicable specified requirements. ISO15189:2022 Clause 8.3.	
document is retained for a specified time or in accordance with applicable specified requirements. ISO15189:2022 Clause 8.3. 1.9 <u>Data Files</u>	Score //
document is retained for a specified time or in accordance with applicable specified requirements. ISO15189:2022 Clause 8.3. 1.9 Data Files Are test results, technical and quality records archived	Score //
document is retained for a specified time or in accordance with applicable specified requirements.ISO15189:2022 Clause 8.3.1.9 Data Files Are test results, technical and quality records archived for a specified period in accordance with the	Score /2
document is retained for a specified time or in accordance with applicable specified requirements.ISO15189:2022 Clause 8.3.1.9 Data Files Are test results, technical and quality records archived	Score //
document is retained for a specified time or in accordance with applicable specified requirements.ISO15189:2022 Clause 8.3.1.9 Data Files Are test results, technical and quality records archived for a specified period in accordance with the	Score //

retrievable for as long as medically relevant or as required by national, regional, or local authorities.			
ISO15189:2022 Clause 8.4			
 1.10 Archived Patient Results Accessibility Is there an archiving system that allows for easy and timely retrieval of patient results as per the requirements of Section 9 of this checklist? Note: Records can be in any form or type of medium, providing they are readily accessible and protected from unauthorised alterations. Archived patient results must be easily, readily and completely retrievable within a timeframe consistent with patient care needs. 		Score	/2
ISO15189:2022 Clause 8.4			
SECTION 01: DOCUMENT AND RI	ECORI	DS	/22

SECTION 02: ORGANISATION AND LEADERSHIP

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field, you may also provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment	
2.1 <u>Procedure and/or Process for Organisational</u> <u>Code of Conduct</u> Has the laboratory defined a procedure and/or a process that addresses, but is not limited to, the following?		Score	/3
 Adherence to organisational policies and procedures; 			
b. Impartiality;			
c. Confidentiality;d. Conflicts of interest.			
ISO15189:2022 Clause 4.1			
 2.2 Implementation of the Organisational Code of Conduct Has the laboratory implemented the procedure and/or process and does it have records of at least, but not limited to, the following? a. Adherence to organisational policies and 		Score	/2
procedures;			
b. Impartiality;c. Confidentiality;			
c. Confidentiality;d. Conflicts of interest.			
ISO15189:2022 Clause 4.1			
2.3 <u>Deputization</u> In the event of the absence of key personnel, has the laboratory implemented a process to ensure the continuity of the laboratory management system?		Score	/2
ISO15189:2022 Clause 5.2.3	T		
2.4 <u>Budgetary Projections</u> Are budgetary projections based on personnel needs, scope of test, infrastructure, equipment needs, service and maintenance and quality assurance process and materials (IQC and EQA)?		Score	/2
ISO15189:2022 Clause 8.2.3	1		
2.5 <u>Routine Review of Quality and Technical</u> <u>Records</u> Does the laboratory routinely perform a documented review of all quality and technical records? Note: There must be documentation that quality records are regularly reviewed and monitored by authorised person(s). This routine review (the laboratory must define their frequency of review, e.g., daily, weekly, monthly) must ensure that recurrent		Score	/3
problems have been addressed and new or redesigned activities have been evaluated.			
a. Follow-up of action items from previous reviews;			
 Status of corrective actions taken and required risk mitigation actions; 			
c. Reports from personnel;			
d. Environmental monitoring logs;			
e. Sample rejection records;			

f Faving and calibration and maintenance records	
f. Equipment calibration and maintenance records;	
g. IQC records across all test areas;	
h. Outcomes of PTs and other forms of inter-laboratory comparisons;	
i. Quality indicators;	
j. Customer complaints and feedback;	
k. Results of improvement projects;	
 Documentation of this routine review and action planning with personnel for resolution and follow-up review. 	
ISO15189:2022 Clause 8.1 and Clause 8.4	
2.6 Procedure and/or Process for Management Review Has the laboratory defined a procedure and/or a process that addresses, but is not limited to, the following?	Score /3
Note: It is recommended that continued progress management review meetings are held to ensure all actions arising are completed within the defined timeframe.	
a. Frequency of management reviews;	
 Review input (agenda as per Clause 8.9.2 of ISO15189:2022); 	
c. Key attendees;	
d. Conduct of review activities;	
e. Review output (decisions, actions to be taken, provision of required resources person responsible and due dates);	
 f. Communication of decisions and actions to be taken to the relevant persons; 	
 Ensure all actions arising are completed within the defined timeframe. 	
ISO15189:2022 Clause 8.9	
2.7 <u>Conduct of Management Reviews</u> Does the laboratory management perform a review and discussion of the laboratory management system at planned intervals?	Score /2
ISO15189:2022 Clause 8.9	
2.8 <u>Management Review Inputs</u> Does the management review meeting include the following inputs?	Score /3
Note: The minimum list of review inputs should include the requirements of Clause 8.9.2 (a-j) of ISO15189:2022.	
 Status of actions from previous management reviews, internal and external changes to the management system, changes in the volume and type of laboratory activities and adequacy of resources; 	
 Fulfilment of objectives and suitability of policies and procedures; 	
 Outcomes of recent evaluations, process monitoring using quality indicators, internal audits, analysis of non-conformities, corrective actions and assessments by external bodies; 	
 d. Patient, user and personnel feedback and complaints; 	
e. Quality assurance of result validity;	
f. Effectiveness of any implemented improvements	
and actions taken to address risks and opportunities for improvement;	

SECTION 02: ORGANISATION AND	LEADERSHIP	/26
ISO15189:2022 Clause 8.9.3		
Note: Laboratory management shall ensure that actions arising from management review and other management meetings are completed within a defined period.		
Does laboratory management ensure that actions from routine technical review and management review meetings are completed within defined timeframes and monitored for their effectiveness?		
2.11 <u>Completion and Monitoring of Review Action</u> Items	Score	/2
ISO15189:2022 Clause 8.9.3		
Note: Findings and actions arising from management reviews shall be recorded and reported to laboratory personnel.		
2.10 <u>Communication of Review Findings</u> Are findings and actions from routine technical and management review meeting communicated to the	Score	/2
ISO15189:2022 Clause 8.9		
e. Any need for change.		
 d. Improvement of services to patients and users; 		
 b. Improvement of the laboratory activities related to the fulfilment of the requirements of this document; c. Provision of required resources; 		
a. Effectiveness of the management system and its processes;		
Note: The interval between management reviews should be no greater than 12 months; however, shorter intervals should be adopted when a Laboratory Management System is being established.		
2.9 <u>Management Review Outputs</u> Does the management review meeting include the following outputs?	Score	/2
ISO15189:2022 Clause 8.9		
j. Other relevant factors, such as monitoring activities and training.		
i. Evaluation of POCT activities;		
h. Results of participation in interlaboratory comparison programs;		
g. Performance of external providers, including referral laboratories and technical consultants;		

SECTION 03: PERSONNEL MANAGEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment	
3.1 <u>Procedure and/or Process for Personnel</u> <u>Management</u> Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?		5	Score /3
Note: The laboratory must have a documented procedure for personnel management and maintain records for all personnel to indicate compliance with requirements.			
 Definition of the structure of the organisation (organisational plan) based on the needs of the laboratory activities; 			
 Definition of job profiles and job descriptions for all laboratory positions; 			
 Selection and recruitment of appropriately qualified personnel; 			
 Orientation of newly recruited and appointed personnel; 			
 Establishment and maintenance of personnel records. 			
ISO15189:2022 Clause 6.2.1			
 3.2 <u>Duty Roster and Daily Routine</u> Does the laboratory have a duty roster that covers normal hours and after hours? Note: A duty roster designates specific laboratory personnel to specific workstations. Daily routines should be prioritised, organised and coordinated to achieve optimal service delivery 		5	Score /2
for patients. ISO15189:2022 Clause 6.2.1			
3.3 <u>Organisational Chart and External/Internal</u> <u>Reporting Systems</u> Is an organisational chart available for indicating the relationship between the laboratory and its parent organisation? Note: An up-to-date organisational chart and/or narrative description should be available detailing the external and internal reporting relationships for laboratory personnel. The organisational chart or narrative should clearly show how the laboratory is linked to the rest of the hospital and laboratory services where applicable.		5	Score /2
ISO15189:2022 Clause 5.4.1			
3.4 <u>Laboratory Management</u> Is the laboratory directed by a person(s) (however named) with specified qualifications, authority, competency and delegated responsibility to perform the following:		5	Score /3
Note: A laboratory director may be a person or persons with responsibility for and authority over a laboratory. The person or persons referred to may be designated collectively as the Laboratory Director. Other settings may not use the term 'Laboratory Director' but in this question, it refers to person/persons that are running the laboratory.			
 Provide effective leadership, budgeting and planning; 			
 b. Communicate with stakeholders; c. Ensure adequate competent personnel; 			
 Ensure adequate competent personnel; 			

d. Ensure the implementation of the quality	
e. Select and monitor laboratory supplies;	
f. Select and monitor referral laboratories;	
g. Ensure a safe laboratory environment;	
h. Provide advisory services;	
i. Provide professional development programmes for laboratory personnel;	
j. Address complaints, requests, or suggestions	
from personnel and or laboratory users; k. Ensure the implementation and application of risk	
assessment program;	
I. Design and implement a contingency plan based	
on the risk assessment program; m. Ensure management and operations of POCT	
activities.	
ISO15189:2022 Clause 5.2.1, Clause 5.2.2 and Clause 5.4.2	
3.5 Compliance with Laboratory Management	Score /2
System	
Is there a person or persons who, irrespective of other responsibilities, have the authority and resources	
needed to carry out their duties, including:	
Note: These roles and responsibilities (quality officer or team) shall be defined, documented, and communicated (e.g., job description, organogram etc.).	
a. Implementation, maintenance, and improvement	
of the management system;	
 Identification of deviations from the management system or from the procedures for performing 	
laboratory activities.	
ISO15189:2022 Clause 5.4.2	
3.6 Procedure and/or Process for Authorisation	Score /3
Has the laboratory defined a procedure and/or	
process that addresses, but is not limited to, the	
following?	
Note: Authorisation may be in the form of a job description, letter of appointment, approved authority matrix, etc.	
a. List of activities that require authorisation;	
b. Defined criteria for authorising persons for specific	
laboratory activities;	
 Documented authorisation for the various activities; 	
d. Appointed deputies for the key positions where	
appropriate.	
ISO15189:2022 Clause 6.2.3	
3.7 <u>Authorisation</u>	Score /2
Are personnel authorised to perform specific	
laboratory activities including, but not limited to, the following:	
a. Selection, development, modification, validation,	
and verification of methods;	
b. Review, release, and reporting of results;	
c. Use of laboratory information systems, particularly	
accessing patient data and information, entering	
patient data and examination results, and changing patient data or examination results.	
ISO15189:2022 Clause 6.2.5	

3.8 Procedure and/or Process for Personnel	Score /3
Training	
Has the laboratory defined a procedure and/or	
process that addresses, but is not limited to, the following?	
Note: Training includes external and internal trainings.	
a. Identification of training needs;	
 Establishment of training programme (including initial and refresher training); 	
c. Provision of a continuous education program;	
d. Recording of training;	
 Evaluation of the effectiveness of the training program. 	
ISO15189:2022 Clause 6.2	
3.9 <u>Laboratory Personnel Training, Continuing</u>	Score /2
Education and Professional Development Is there a programme for training, continuing	
education and professional development including,	
but not limited to, the following:	
 Laboratory management system; 	
b. Induction to the organisation;	
c. Assigned work processes, procedures, and tasks;	
d. Applicable laboratory information system;	
e. Health and safety, including the prevention or	
containment of the effects of adverse incidents;	
f. Laboratory ethics, impartiality and confidentiality of patient information;	
g. Supervision of persons undergoing training,	
 Continuous education (advancement in laboratory practice, clinical diagnostics, surveillance, etc.); 	
i. Review of effectiveness of the training program.	
ISO15189:2022 Clause 6.2	
3.10 Procedure and/or Process for Competency	Score /3
Assessment	
Has the laboratory defined a procedure and/or a process that addresses, but is not limited to, the	
following?	
Note: Competency could be assessed using a combination of	
some or all the following methods: direct observation,	
monitoring and recording of examination results, review of	
work records, problem solving skills, blinded samples, review of accumulative IQC and EQA. Competency assessment for	
professional judgment should be designed as specific and fit	
<i>for purpose.</i> a. Defining the methods of performing competency	
assessment;	
b. Defining the competency requirements, criteria	
and frequency for each laboratory activity or	
function (managerial or technical tasks);c. Assessment of ongoing competency;	
 d. Providing feedback (verbal, written, etc.) to persons assessed; 	
 Scheduling retraining based on assessment outcomes; 	
f. Retention of records of competency assessments	
and outcomes.	

1 2 4	1 Implementation of Dresselves and/or		Coore	10
3.1	1 Implementation of Procedure and/or Process of Personnel Competency		Score	/2
Do	es the laboratory assess the competency of its			
	sonnel according to its defined criteria for all			
	evant activities including the following:			
	evant dervices mordaring the following.			
	te: Newly hired laboratory personnel must be assessed for			
	npetency before performing duties independently. sonnel assigned to a new section should be assessed			
	ore fully assuming new duties independently. When			
def	iciencies are noted, retraining and reassessment must be			
	nned and documented. If the employee's competency			
	essment consistently remains below standard, further ion might include supervisory review of work, re-			
	ignment of duties, or other appropriate actions. Records of			
	npetency assessments and resulting actions should be			
	ained in personnel files and/or quality records.			
а.	Records that indicate which skills were assessed,			
	how those skills were measured, and who			
	performed the assessment;			
b.	Competency assessments performed according to			
	defined criteria for new hires and existing			
	personnel;			
C.	Retraining and re-assessment where needed.			
ISC	015189:2022 Clause 6.2.2			
3.1	2 Procedure and/or Process for Review of		Score	/2
	Personnel Performance			
	s the laboratory defined a procedure and/or			
•	ocess that addresses, but is not limited to, the			
	owing?			
а.	Planning and performing personnel performance			
_	appraisals;			
b.	Establishing frequency of monitoring and			
	reviewing of personnel performance outcome;			
C.	Keeping records of personnel performance.			
ISC	015189:2022 Clause 6.2.2 and Clause 8.1.3 b)			
<i>ISC</i> 3.1	15189:2022 Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings		Score	/2
<i>ISC</i> 3.1 Are	 and Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings be personnel meetings held regularly and do they 		Score	/2
<i>ISC</i> 3.1 Are	15189:2022 Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings		Score	/2
ISC 3.1 Are ade	015189:2022 Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items?		Score	/2
ISC 3.1 Are add	015189:2022 Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings		Score	/2
ISC 3.1 Are add Not	015189:2022 Clause 6.2.2 and Clause 8.1.3 b) 3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items?		Score	/2
ISC 3.1 Are add Not to e sho	 Presented and Clause 8.1.3 b) Personnel Meetings personnel meetings held regularly and do they dress the following meeting items? The laboratory should hold regular personnel meetings ensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. 		Score	/2
ISC 3.1 Are add Not to e sho	a Personnel Meetings b Personnel Meetings b personnel meetings held regularly and do they c personnel meetings held regularly and do they d dress the following meeting items? d the second progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel		Score	/2
ISC 3.1 Are add Not to e sho pro a.	a Personnel Meetings b personnel meetings held regularly and do they dress the following meeting items? b the laboratory should hold regular personnel meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings;		Score	/2
ISC 3.1 Are add Not to e sho pro a.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings ensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues		Score	/2
ISC 3.1 Are add Not to e sho pro a.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings multiple personnel meetings held regular personnel meetings te: The laboratory should hold regular personnel meetings multiple personnel meetings te: The laboratory should hold regular personnel meetings multiple personnel meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent		Score	/2
ISC 3.1 Are add Not to e sho pro a.	 Parts of the second s		Score	/2
ISC 3.1 Are add Not to e sho pro a.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings multiple personnel meetings held regular personnel meetings te: The laboratory should hold regular personnel meetings multiple personnel meetings te: The laboratory should hold regular personnel meetings multiple personnel meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent		Score	/2
ISC 3.1 Are add to e sho pro a.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings ensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints;		Score	/2
ISC 3.1 Are add to e sho pro a. b.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant		Score	/2
ISC 3.1 Are add to e sho pro a. b.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings ansure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management		Score	/2
ISC 3.1 Are add to e sho pro a. b.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings ansure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system;		Score	/2
ISC 3.1 Are add Not to a sho pro a. b. C. d.	3 Personnel Meetings a personnel meetings held regularly and do they dress the following meeting items? b the following meeting items? c complaints; c communica		Score	/2
ISC 3.1 Are add Not sho pro a. b. C. d.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings bould have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement		Score	/2
ISC 3.1 Are add Not sho pro a. b. c. d. e. f.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings bould have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects;		Score	/2
ISC 3.1 Are add Not to a sho pro a. b. C. d.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings multiple b personnel meetings held regular personnel meetings te: The laboratory should hold regular personnel meetings multiple b personnel meetings held regular personnel meetings te: The laboratory should hold regular personnel meetings b personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended		Score	/2
ISC 3.1 Are add Not sho pro a. b. c. d. e. f.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings meeting items? te: The laboratory should hold regular personnel meetings meeting items? te: The laboratory should hold regular personnel meetings mean including meeting items? te: The laboratory should hold regular personnel meetings multiple build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external		Score	/2
ISC 3.1 Are add Not to e sho pro a. b. c. d. e. f. g.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings meeting items? te: The laboratory should hold regular personnel meetings meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.;		Score	
ISC 3.1 Are add Not sho pro a. b. c. d. e. f.	3 Personnel Meetings e personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings sensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.; Provide advisory and/or interpretation of		Score	
ISC 3.1 Are add Not to e sho pro a. b. c. d. e. f. g.	3 Personnel Meetings a personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings ansure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.; Provide advisory and/or interpretation of laboratory results and updates on laboratory		Score	
ISC 3.1 Are add Not to e sho pro a. b. c. d. e. f. g.	3 Personnel Meetings a personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings sensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.; Provide advisory and/or interpretation of laboratory results and updates on laboratory attendance at meetings with clinicians (use of		Score	
ISC 3.1 Are add Not sho pro a. b. c. d. e. f. g. h.	 Personnel Meetings Personnel Meetings personnel meetings held regularly and do they dress the following meeting items? the intervention of the progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.; Provide advisory and/or interpretation of laboratory results and updates on laboratory attendance at meetings with clinicians (use of laboratory services); 		Score	
ISC 3.1 Are add Not to e sho pro a. b. c. d. e. f. g.	3 Personnel Meetings a personnel meetings held regularly and do they dress the following meeting items? te: The laboratory should hold regular personnel meetings sensure communication within the laboratory. Meetings build have recorded progress notes to facilitate the review of gress over time. Follow-up of action items from previous personnel meetings; Systemic and/or recurrent problems and issues addressed, including actions to prevent recurrence; Complaints; Communication on reviewed/revised/redundant SOPs and changes to the laboratory management system; Review of results from prior to corrective actions; Discussion and evaluation of improvement topics/projects; Feedback given by personnel that have attended hospital meetings, clinical rounds, external meetings, training, conferences, workshops, etc.; Provide advisory and/or interpretation of laboratory results and updates on laboratory attendance at meetings with clinicians (use of		Score	

j. Importance of meeting needs and requirements of users and management system (ISO15189:2022).	
ISO15189:2022 Clause 5.3.2	
3.14 Personnel Records Are records of personnel maintained (hardcopy or electronic copy) and do they include the following? Note: Personnel files must be maintained for all current personnel. Wherever (offsite or onsite) and however the records are kept, the records must be easily accessible. In some laboratories, not all personnel records may be kept in a single file in one place, e.g., training and competency records may be kept in the laboratory, whereas medical and health information may be kept with the administration department.	Score /3
a. Educational and professional qualifications;	
 Determination of the competency requirements specified in Section 3 of this checklist; 	
 Job descriptions in relation to the designated position; 	
d. Training and re-training;	
e. Authorisation of personnel;	
f. Monitoring of competency of personnel.	

SECTION 04: CUSTOMER FOCUS

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y)". Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment		
4.1 Procedure and/or Process for Advisory			Score	/3
Services Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?				
a. Advice on the choice of examinations;				
b. Communication of advisory services to its users;				
 Advice on clinical indications and limitations of examination procedures; 				
d. Advise on the frequency of examinations;				
e. Provision of individual clinical advice;				
f. Advice on interpretation of results;				
 g. Promotion of the effective utilisation of laboratory services; 				
h. Consultation on scientific and logistic matters;				
 Advice on required sample types and volumes for testing. 				
Note: This information may be available in the Laboratory Handbook or website, etc.				
ISO15189:2022 Clause 5.3.3	l in the second s			
4.2 Advice and Instruction by Qualified Personnel Do laboratory personnel with appropriate professional qualifications provide patients and users with advice and/or training regarding required types of samples, choice of examinations, repeat frequency, and interpretation of results? Note: Authorised (trained and competent) personnel should provide advice on sample type, examination choice, frequency,			Score	/2
and result interpretation. ISO15189:2022 Clause 5.3.3				
4.3 Procedure and/or Process for Handling of Complaints and Feedback Has the laboratory defined a procedure and/or process that addresses, but is not limited, the following?			Score	/3
a. Receipt and acknowledgment of complaints;				
 Investigation and action taken from complaints and feedback (where relevant); 				
c. Tracking and recording of complaints and feedback (where relevant);				
d. Defining timeframes for closure and feedback to the complainant;				
e. Monitoring the effectiveness of corrective actions taken on complaints and feedback to complainant.				
ISO15189:2022 Clause 7.7				
4.4 <u>Receipt and Resolution of Complaints</u> Does the laboratory implement a process for the receipt and resolution of complaints? (Are there records of the original complaint and tracking and feedback?) Note: Feedback includes acknowledgment of receipt and resolution of complaint			Score	/2
resolution of complaint.				

45 Deminemente Devending Detiente	6 a a ma
4.5 <u>Requirements Regarding Patients</u>	Score /2
Has the laboratory established and implemented a	
process for treatment of patients' well-being, samples, or remains, with due care and respect?	
or remains, with due care and respect?	
Note: Code of Ethics may be defined to satisfy the above requirements.	
ISO15189:2022 Clause 4.3 e)	
4.6 Procedure and/or Process for Service	Score /3
Agreements (including POCT)	
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
a. Establishment of service agreements (requirements	
are specified);	
b. Review and approval of service agreements	
(capability and adequate resources);	
c. Management of walk-in patients (where applicable);	
d. Communication of changes of the service	
agreement that affect examination results;	
e. Communication to the requester of any work that	
has been referred;	
f. Defining specified responsibilities and authorities for	
POCT activities in the service agreements.	
ISO15189:2022 Clause 6.7	
4.7 Implementation of the Procedure and/or	Score /3
Process for Service Agreements (including	
POCT)	
Has the laboratory implemented a procedure and/or	
process and have records including but not limited to	
the following?	
a. Establishment of service agreements (requirements	
are specified);	
b. Review and approval of service agreements	
(capability and adequate resources);	
c. Management of walk-in patients, (where applicable);	
d. Communication of changes of the service	
agreement that affect examination results;	
e. Communication to the requester of any work that	
has been referred;	
f. Definitions of specified responsibilities and	
authorities for POCT activities in the service	
agreements.	
ISO15189:2022 Clause 6.7	
4.8 Laboratory Information for Patients and Users	Score /2
Is laboratory information available for patients and	
laboratory users in the language understood by the	
community?	
Note 1: Laboratory information may be in the form of Laboratory Handbook, brochure, videos, website, etc.	
Note 2: The laboratory should provide its clients with a handbook that outlines the laboratory hours of operation, available tests, sample collection instructions, packaging, and shipping directions, and expected turnaround times.	
ISO15189:2022 Clause 7.2	

4.9 <u>Communication Policy on Delays in Service</u> Is timely-documented notification provided to patients	Score /2
and users when the laboratory experiences delays or	
interruptions in testing (due to equipment failure, stock	
outs, personnel levels, etc.) or finds it necessary to	
change examination procedures and when testing	
resumes?	
Note 1: There must be a policy for notifying patients or users when the laboratory experiences delays or interruptions in testing	
Note 2: There must be records of communication. Communication may be in the form of telephonic messages, memos, emails, etc. There must be records of communication when an examination is delayed to the requester and or clinical	
personnel.	
ISO15189:2022 Clause 7.4.1.1 b)	
4.10 Utilisation of Customer Feedback	Score /2
Are there opportunities for laboratory patients, users	
and personnel to provide information to aid the laboratory in improving its management system,	
laboratory activities, and services to users?	
Note 1: The laboratory should measure the satisfaction of	
patients, users, and personnel regarding its services on an ongoing basis.	
Note 2: There must be records of feedback including actions taken.	
ISO15189:2022 Clause 8.6.2	
	10.1
SECTION 04: CUSTOMER FOCUS	/24

SECTION 05: EQUIPMENT MANAGEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

REQUIRE	MENTS	Y/P/N/ NA	Comment		
	dure and/or Process for Management of ratory Equipment			Score	/3
Has the lab	poratory defined a procedure and/or process ses, but is not limited to, the following?				
a. Determ	ining the need and specification of equipment;				
b. Selection	on of equipment;				
c. Procure	ement of equipment;				
d. Accepta	ance and installation;				
	n and maintenance of equipment records ng the equipment service schedule);				
	labelling of equipment (serial number, asset , date of calibration, etc.);				
frequen					
deconta	ement of defective equipment (including amination);				
equipm	g and authorisation of personnel to operate ent use;				
j. Manage	ement of obsolete equipment;				
	ement of safe handling, transportation, storage to avoid deterioration and contamination;				
	g and verification of completion of repairs and				
ISO15189:202		l			
Does the la	s to Required Equipment boratory have access to the required for the performance of laboratory activities?			Score	/2
ISO15189:202		-			
ls equipme operator's r <i>Note: Equipn</i> <i>manual away</i>	ence to Proper Equipment Protocol nt installed and placed as specified in the manuals and uniquely labelled or marked? ment should be properly placed as specified in the user of from potential hazards including but not limited to the atter, direct sunlight, vibrations, traffic.			Score	/2
ISO15189:202	22 Clause 6.4	1			
Equipment	ment operated by trained, competent and			Score	/2
available.	Is of training, competency and authorisation shall be				
	22 Clause 6.4.4 b)				
Verifi Has the lab that addres	dure and/or Process for Validation and ication of Equipment oratory defined a procedure and/or process ses, but is not limited to, the following? o CLSI documents for guidance, e.g., QMS23-ed2.			Score	/3
a. Defining	g the validation or verification protocol				
	ng the authorisation for the intended use); ning equipment verification or validation;				

c. Defining verification or validation report.	
ISO15189:2022 Clause 6.4	
5.6 Equipment Verification and Documentation	Score /3
Is all equipment verified onsite upon installation after	
maintenance and repair before use?	
Note: Newly introduced equipment must be verified onsite to ensure that its introduction yields performance equal to or better than the previous equipment. Manufacturers' validation information may be used. Back-up equipment must also be included in verification procedures.	
a. Are specific verification protocols in place for each item of equipment?	
b. Has validation information been obtained from the manufacturer as part of the verification?	
c. Have performance characteristics been appropriately	
selected and evaluated as per intended use?	
d. Were the verification studies appropriate and	
adequate?	
e. Was the analysis of data appropriate for the selected performance characteristics?	
f. Have the verification results and reports been	
reviewed and approved by an authorised person?	
ISO15189:2022 Clause 6.4.3	
5.7 Equipment Records	Score /3
Is current equipment inventory data available for all equipment in the laboratory?	
a. Manufacturer and supplier details, and sufficient	
information to uniquely identify each item of equipment, including software and firmware;	
 Dates of receipt, acceptance testing and entry into service; 	
 Evidence of verification or validation that equipment conforms with specified acceptability criteria; 	
d. Current location of equipment;	
 Condition when received (e.g., new, used, or reconditioned); 	
f. Manufacturer's instructions;	
g. Programme for preventive maintenance;	
 Maintenance activities performed by the laboratory or approved external service provider; 	
 Damage to, malfunction, modification, or repair of the equipment; 	
 Equipment performance records, such as reports or certificates of calibrations or verifications, or both, 	
including dates, times, and results;	
k. Date of last service;	
I. Date of next service.	
ISO15189:2022 Clause 6.4.7	
5.8 Defective Equipment Waiting for Repair	Score /2
Is defective equipment waiting for repair not used and clearly labelled?	
Note 1 Labels should include the date of malfunction and 'not in use' and signature of approval.	
Note 2: All equipment malfunctions must be investigated and documented as per the non-conforming procedure. If the user cannot resolve the problem, a repair order must be initiated.	
ISO15189:2022 Clause 6.4.5	

5.9 <u>Obsolete Equipment</u> Is obsolete equipment appropriately labelled and removed	Score /2
from the laboratory or path of workflow?	
ISO15189:2022 Clause 6.4.5	
5.10 Procedure and/or Process for Calibration of	Score /3
Equipment	
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
a. Frequency of calibration;	
 b. Handling of in-house calibrations (pipettes, thermometers, timers, etc.); 	
 Management of calibrations performed by external service providers; 	
d. Recording of metrological traceability;	
e. Handling of failed calibrations;	
f. Retention of calibration records (use of stickers and calibration certificates).	
ISO15189:2022 Clause 6.5	
5.11 Equipment Calibration and Metrological	Score /3
Traceability	
Note: Desumentation of calibration traceshility to a higher order	
Note: Documentation of calibration traceability to a higher order reference material or reference procedure may be provided by an	
examination system manufacturer. Such documentation is	
acceptable if the manufacturer's examination system and calibration procedures are used without modification.	
a. Is routine calibration of laboratory measuring	
equipment (including pipettes, centrifuges, balances,	
and thermometers) scheduled, at minimum following	
manufacturer's recommendations?b. When routine calibration of laboratory measuring	
equipment (including pipettes, centrifuges, balances,	
and thermometers) is performed offsite (externally),	
are there records of verification before use?	
c. Is information on metrological traceability (e.g., use of	
reference materials and equipment like certified	
thermometers, tachometer) available?	
Note: Calibration certificates, calibration reports, etc. may be used as records of metrological traceability information.	
d. Is there evidence of review of calibrations records	
(e.g., calibration certificates, calibration reports, etc.)	
by the laboratory before acceptance back into use?	
e. Where it is not possible to provide traceability using	
an accredited calibration laboratory, are certified reference materials, examination and calibration by	
another procedure, use of mutual consent standards	
or methods used for in house calibrations?	
ISO15189:2022 Clause 6.5.3 c)	
5.12 Equipment Preventive Maintenance	Score /2
Is routine user preventive maintenance performed on all	
equipment and recorded according to manufacturer's	
minimum requirements?	
Note: Preventative maintenance by operators must be done on all equipment used in examinations including centrifuges, autoclaves, microscopes, and safety cabinets.	
ISO15189:2022 Clause 6.4.5	
130 13 103.2022 Glause 0.4.3	

5.13 Equipment Service Maintenance Is equipment routinely serviced according to a schedule as per the minimum manufacturer's recommendations by approved internal or external service providers and is this information documented in appropriate logs? Note: All equipment must be serviced at specified intervals by a qualified service engineer either through service contracts or otherwise. Service schedules must at minimum meet manufacturer's requirements ISO15189:2022 Clause 6.4.5			Score	/2
			Score	/2
5.14 Equipment Adverse Incident Reporting.			Score	12
 Are there records of investigation, identification and implementation of corrective actions taken and follow- up? 				
 b. Is there documentation of reports made to manufacturers or suppliers and appropriate authorities of adverse incidents and accidents where applicable? 				
ISO15189:2022 Clause 6.4.6				
5.15 <u>Manufacturer's Operator Manual</u> Are the manufacturer's operator manuals readily available to testing personnel and available in the language understood by personnel?			Score	/2
ISO15189:2022 Clause 6.4.4				
5.16 <u>Use of Equipment</u> Are there precautions (e.g., password protection) in place to prevent unintended adjustments of automated equipment, where applicable?			Score	/2
ISO15189:2022 Clause 6.4.4				
SECTION 05: EQUIPMENT MANAG	EMEN [.]	Т	/3	8

SECTION 06: ASSESSMENTS
For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must
be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment
field you may also provide information on what was audited, i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment	
6.1 Procedure and/or Process for Internal Audits		Score /3	3
Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?			
Note 1: Inputs into planning, scheduling and conduct of internal audits may include:			
i. Priority given to risk posed to patients resulting from laboratory activities;			
ii. Identified risks;			
iii. Outcomes of both external evaluations and previous internal audits;			
 iv. Occurrence of nonconformities, incidents, and complaints; v. Changes affecting the laboratory activities. 			
Note 2: The cycle for internal auditing should normally be completed in one year. It is not necessary that internal audits cover each year, in depth, all elements of the Laboratory Management System.			
a. Inputs into planning, scheduling, and conduct of			
internal audits; b. Scheduling of internal audits;			_
			
c. Frequency of internal audits;			
d. Scope of internal audits;			
e. Criteria for internal audits;			
f. Selection of internal auditors;			
g. Recording of audit findings;			
h. Addressing identified nonconformities;			
i. Implementation of corrective actions;			
j. Monitoring of the effectiveness of corrective actions.			
ISO15189:2022 Clause 8.8.3			
6.2 Internal Audits		Score /3	3
Are internal audits conducted at intervals as defined in the			
internal audit programme and do these audits address all areas of the laboratory management systems?			
Note: The cycle for internal auditing should normally be completed in			
one year and at planned intervals.			
Is there an audit programme that ensures all activities of the laboratory are audited?			
Note: Internal auditing shall cover all activities in the Laboratory Management System, including pre-examination, examination, and post-examination			
a. Are audits being carried out with minimal conflict of			
interest where possible, carried out by persons who are not involved in activities in the section being audited?			
b. Are the personnel conducting the internal audits trained, qualified, and authorised to conduct internal audits?			
c. Are internal audit findings documented and presented to			
laboratory management and relevant personnel for			
review? ISO15189:2022 Clause 8.8.3	l		
6.3 Audit Recommendations and Action Plan and		Score /3	2
Follow-up			-

a. Are internal audits reports generated, disseminated, and communicated to laboratory management and relevant personnel for review? b. Is an action plan developed with clear timelines, assigned personnel and documented follow-up within the timeframe defined by laboratory management? c. Are recommendations for improvement actions made based on audit findings? Mote: For actions that are not implemented as per the due dates there should be a motivation and an approval of extension. ISO15189:2022 Clause 8.8.3 6.4 Procedure and/or Process for Risk Management Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and post-examination processes. The laboratory shall evaluate the impact of work processes and post-examination recesses and post-examination recesses and post-examination recesses and post-examination recesses. The laboratory shall evaluate the impact of work processes and post-examination recesses and post-examination recesses. The laboratory shall evaluate the impact of work processes and post-examination recesses a
b. Is an action plan developed with clear timelines, assigned personnel and documented follow-up within the timeframe defined by laboratory management? . c. Are recommendations for improvement actions made based on audit findings? . Note: For actions that are not implemented as per the due dates there should be a motivation and an approval of extension. . ISO15189:2022 Clause 8.8.3 . 6.4 Procedure and/or Process for Risk Management addresses, but is not limited to, the following? . Note: Risk must be managed at the pre-examination processes, reamination processes and post-examination processes. The laboratory patient extension and a ball modify processes to reduce or eliminate the identified risks and the consideration patient care and laboratory advites. . a. Methods used to identify risks and opportunities; . . b. Areas for identifying risks and opportunities; . . c. Development of action plans to address both risks and opportunities; . . d. Evaluation of the effectiveness of implemented actions and modification where required; . . e. Recording and communication of decisions made, and actions taken on risks and opportunities. . . b. Areas for identifying risks and opportunities. . . . b. Areas for identifying risks and opportunities. . . .
assigned personnel and documented follow-up within the timeframe defined by laboratory management? . c. Are recommendations for improvement actions made based on audit findings? . Note: For actions that are not implemented as per the due dates there should be a motivation and an approval of extension. . ISO15189:2022 Clause 8.8.3 . 6.4 Procedure and/or Process for Risk Management Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? . Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes, the laboratory shall evaluate the impact of work processes and potential failures on examination results as they affect patient safety and shall modify processes to reduce or alboratory activities. . b. Areas for identify risks and opportunities; . . c. Development of action plans to address both risks and opportunities or improvement; . . d. Evaluation of the effectiveness of implemented actions and modification where required; . . e. Recording and communication of decisions made, and actions taken on risks and opportunities. . . ISO15189-2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 . . c. Recording and communication of decisions made, and actions taken on risks and opportunities. . . . <
c. Are recommendations for improvement actions made based on audit findings? Note: For actions that are not implemented as per the due dates there should be a motivation and an approval of extension. ISO15189:2022 Clause 8.8.3 6.4 Procedure and/or Process for Risk Management Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and potential failures on examination results as they affect patient safety and shall modify processes to reduce or eliminate the identified risks and occument decisions and actions taken. Risk management must take into consideration patient care and laboratory activities. Score 73 a. Methods used to identify risks and opportunities associated with its examinations and activities; D D D b. Areas for identify nisks and opportunities associated and modification where required; E E E Recording and communication of decisions made, and actions taken on risks and oppoportunitites. E Score
should be a motivation and an approval of extension. ISO15189:2022 Clause 8.8.3 6.4 Proceedure and/or Process for Risk Management Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and potential failures on examination processes or eliminate the identified risks and document decisions and actions taken. Risk management must take into consideration patient care and laboratory activities. a. Methods used to identify risks and opportunities associated with its examinations and activities; E b. Areas for identifying risks and opportunities associated with its examinations and activities; E c. Development of action plans to address both risks and opportunities for improvement; E d. Evaluation of the effectiveness of implemented actions and modification where required; E e. Recording and clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 6.5 Risk Management Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: Score /3 a. Impartiality; b. Confidentiality; E Score /3
ISO15189:2022 Clause 8.8.3 6.4 Procedure and/or Process for Risk Management Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and potential failures on examination results as they addect patient safety and shall modify processes to reduce or eliminate the identified risks and document decisions and actions taken. Risk management must take into consideration patient care and laboratory activities; Score /3 a. Methods used to identify risks and opportunities; Areas for identifying risks and opportunities; Score /3 b. Areas for identifying risks and opportunities; Development of action plans to address both risks and opportunities for improvement; d. Evaluation of the effectiveness of implemented actions and modification where required; Score /3 e. Recording and communication of decisions made, and actions taken on risks and opportunities. Score /3 ISO15189:2022 Clause 5.6 and Clause 8.5; ISO2367:2020; ISO35001:2019; ISO31000:2018 Score /3 6.5 Risk Management Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. Impartiality; b. Confidentiality; Score /
Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and potential failures on examination results as they affect patient safety and shall modify processes to reduce or eliminate the identified risks and document decisions and actions taken. Risk management must take into consideration patient care and laboratory activities; a. Methods used to identify risks and opportunities; b. b. Areas for identifying risks and opportunities; c. c. Development of action plans to address both risks and opportunities for improvement; c. d. Evaluation of the effectiveness of implemented actions and modification where required; e. e. Recording and communication of decisions made, and actions taken on risks and opportunities. score /3 ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 Score /3 6.5 Risk Management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. a. Impartiality; b. Confidentiality;
Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Risk must be managed at the pre-examination processes, examination processes and post-examination processes. The laboratory shall evaluate the impact of work processes and potential failures on examination results as they affect patient safety and shall modify processes to reduce or eliminate the identified risks and document decisions and actions taken. Risk management must take into consideration patient care and laboratory activities; a. Methods used to identify risks and opportunities; b. b. Areas for identifying risks and opportunities; c. c. Development of action plans to address both risks and opportunities for improvement; c. d. Evaluation of the effectiveness of implemented actions and modification where required; e. e. Recording and communication of decisions made, and actions taken on risks and opportunities. score /3 ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 Score /3 6.5 Risk Management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. a. Impartiality; b. Confidentiality;
examination processes and post-examination processes. The laboratory shall evaluate into impact of work processes and potential failures on examination results as they affect patient safety and shall modify processes to reduce or eliminate the identified risks and document decisions and actions taken. Risk management must take into consideration patient care and laboratory activities. a. Methods used to identify risks and opportunities; b. Areas for identifying risks and opportunities; c. Development of action plans to address both risks and opportunities for improvement; d. Evaluation of the effectiveness of implemented actions and modification where required; e. Recording and communication of decisions made, and actions taken on risks and opportunities. ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 6.5 Risk Management trogramme that identifies risks and opportunities risks and opportunities for improvement in all laboratory processes including but not limited to: a. Impartiality; b. Confidentiality;
b. Areas for identifying risks and opportunities associated with its examinations and activities;
with its examinations and activities; c. Development of action plans to address both risks and opportunities for improvement; d. Evaluation of the effectiveness of implemented actions and modification where required; e. Recording and communication of decisions made, and actions taken on risks and opportunities. ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 6.5 Risk Management Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. Impartiality; b. Confidentiality;
opportunities for improvement;
and modification where required; implemented e. Recording and communication of decisions made, and actions taken on risks and opportunities. implemented ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 Score 6.5 Risk Management Score /3 Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: impartiality; b. Confidentiality; impartiality; impartiality;
actions taken on risks and opportunities. ISO15189:2022 Clause 5.6 and Clause 8.5; ISO22367:2020; ISO35001:2019; ISO31000:2018 6.5 Risk Management Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: Score /3 a. Impartiality; b. Confidentiality; Impartiality; Impartiality;
6.5 <u>Risk Management</u> Score /3 Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. Impartiality; b. Confidentiality;
Has laboratory management developed and implemented a risk management programme that identifies risks and opportunities for improvement in all laboratory processes including but not limited to: a. a. Impartiality; b. b. Confidentiality; b.
b. Confidentiality;
c. Structural and governance requirements:
d. Personnel;
e. Facilities and environmental activities;
f. Equipment;
g. Reagents and consumables;
h. Service agreements;
i. Externally provided products and services
j. Pre-examination processes;
k. Examination processes (including POCT);
I. Post-examination processes;
m. Nonconforming work;
n. Control of data and information management;
o. Complaints;
p. Management system documentation;
q. Control of management system documents;

t. Evaluations;	
u. Management review.	
ISO15189:2022 Clause 5.6; ISO22367:2022	
6.6 <u>Risk Management Assessment</u> Does the laboratory use evaluation tools to identify risks and opportunities for improvements?	Score /2
Note: Tools such as brainstorming, SWOT analysis, 5 WHYs	
a. Internal audits;	
b. Customer complaints/feedback;	
c. Nonconforming event management;	
d. Management review;	
e. Quality indicators	
ISO15189:2022 Clause 5.6	
6.7 <u>Risk and Opportunities Action Plan</u>	Score /3
 a. Is an action plan for identified risks and opportunities for improvement developed and implemented with clear timelines and responsibilities? 	
b. Does laboratory management evaluate the effectiveness of the risk and/or opportunities for improvement action plan?	
c. Are actions modified when actions are identified as being ineffective?	
ISO15189:2022 Clause 5.6	
6.8 <u>Quality Indicators</u> Are quality indicators selected to cover pre-examination, examination, and post-examination processes (e.g., turnaround times, rejected samples, stock-outs, etc.), defined, measured, and monitored? Note 1: The identification of the quality indicators should include	Score /2
establishing the objectives, methodology, interpretation, limits, action plan and duration of monitoring.	
Note 2: The laboratory should select quality indicators in line with meeting its objectives from pre-analytic, analytic, and post-analytic phases critical to patient outcomes.	
ISO15189:2022 Clause 8.8.3 and Clause 5.5 d)	
6.9 <u>Monitoring of Quality Indicators</u> Are the outcomes of the review of quality indicators used to improve laboratory processes?	Score /2
Note: The laboratory should review the quality indicators at defined intervals.	
ISO15189:2022 Clause 8.8.2 and Clause 5.6; ISO22367:2022	
SECTION 06: ASSESSMENTS	/24

SECTION 07: SUPPLIER AND INVENTORY MANAGEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment		
7.1 <u>Procedure and/or Process for Externally Provided</u>			Score	/3
Products and Services Has the laboratory defined a procedure and/or process that				
addresses, but is not limited to, the following?				
a. Selection of required products and services;				
b. Establishment of selection criteria;				
c. Establishment of acceptance criteria;				
 Selection, approval of suppliers and technical consultants; 				
e. Maintenance of approved suppliers list;				
f. Defining the requirements of its purchase supplies and services (purchase documentation);				
 Reviewing and monitoring of the performance of its approved suppliers; 				
h. Frequency of reviewing and monitoring the performance.				
ISO15189:2022 Clause 6.8				
7.2 <u>Procedure and/or Process for Purchasing and</u> Inventory Control of Equipment, Reagents, and			Score	/3
Consumables				
Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?				
a. Requisition, ordering and receipt of purchased items;				
b. Establishment of acceptance and rejection criteria for				
purchased items;				
c. Acceptance testing;				
d. Storage of purchased items;				
e. Management of inventory;				
f. Monitoring and handling of expired items;				
g. Responding to manufacturers recall or other notices.				
ISO15189:2022 Clause 6.8.3	-			
7.3 Inventory and Budgeting System (Including the requirements for POCT)			Score	/2
Is there a process for accurately forecasting needs for				
services, supplies and reagents?				
Note 1: External services include referral laboratories and consultants.				
Note 2: The laboratory must have a systematic way of determining its supply and testing needs through inventory control and budgeting systems that take into consideration past patterns, present trends,				
and future plans.				
ISO15189:2022 Clause 6.6.1	-			12
7.4 <u>Purchasing Specifications</u> Does the laboratory provide specifications for their services,			Score	/2
supplies and consumables that are required when placing a				
requisition?				
Note: Specification could be in the form of catalogue number, item number, manufacturer name, etc.				
ISO15189:2022 Clause 6 6 1				

		-
7.5 <u>Service Supplier Performance Review</u>	Score	/2
Does laboratory management monitor the performance of		
external suppliers (including referral laboratories, technical		
consultants, and EQA providers) to ensure that they		
continually meet the stated criteria of the approved		
suppliers?		
Note: All suppliers of services used by the laboratory must be		
reviewed and monitored for their performance. ISO15189:2022 Clause 6.8.3 a) and c)		
7.6 Inventory Control	Score	/3
Does the laboratory maintain records for each reagent and		/0
consumable that contributes to the performance of		
examinations? These records shall include but not be limited		
to the following:		
a. Identity of the reagent or consumable;		
b. Batch code or lot number;		
c. Manufacturer or supplier name and contact information;		
d. Received date, expiration date, date of entry into service		
and date material was taken out of service, where		
applicable;		
e. Manufacturer's instruction/package insert;		
f. Records of inspection of reagents and consumables		
when received (e.g., acceptable or damaged);		
Note: All incoming orders must be inspected for condition and		
completeness of the original requests, receipted, and documented		
appropriately, date received in the Laboratory and expiry date for the		
<i>product should be clearly indicated.</i> g. Reference to the person or persons undertaking the		
preparation of reagents, resuspension or combined in-		
house, as well as the dates of preparation and stability.		
Note: The above the information(a-g) may be captured on the actual item but is also required to be captured on the inventory log.		
ISO15189:2022 Clause 6.6.7		
7.7 Management Review of Supply Requests	Score	/2
Does laboratory management review and approve the		
laboratory's requirements for all externally provided products		
and services?		
Note: Since laboratories have different purchasing approval systems,		
there should be a system in place that the laboratory reviews final approval of their original request.		
ISO15189:2022 Clause 6.8.3		
7.8 Laboratory Inventory System	Score	/2
Note: The laboratory inventory system should reliably inform		
personnel of the minimum amount of stock to be kept to avoid interruptions of service due to stock-outs and the maximum amount		
to be kept by the laboratory to prevent expiry of reagents.		
a. Are inventory records complete and accurate with		
minimum and maximum stock levels denoted and		
monitored?		
b. Is the consumption rate of all reagents and consumables monitored?		
c. Are inventory/stock counts routinely performed?		
ISO15189:2022 Clause 6.6.4		10
7.9 <u>Storage Area</u> Are storage areas set up and monitored appropriately?	Score	/2
The storage areas set up and monitored appropriately:		
Note: Storage of supplies and consumables must be as per the manufacturer's specifications.		
a. Is the storage area well-organised and free of clutter to		
prevent damage and deterioration?		

b. Are there designated places for all inventory items for easy access (separation of inspected and uninspected items)?	
c. Is adequate cold storage available?	
 d. Is the humidity of the room monitored routinely, when appropriate? 	
e. Is the temperature of the room monitored routinely?	
f. Is storage in direct sunlight avoided? Is direct sunlight avoided in storage areas?	
g. Is the storage area adequately ventilated?	
h. Is the storage area clean and free of dust and pests?	
i. Are storage areas access-controlled?	
ISO15189:2022 Clause 6.6.2	
7.10 Inventory Organisation and Wastage Minimisation Is First-Expiration-First-Out (FEFO) practiced?	Score /2
Note: To minimise wastage from product expiration, inventory should be organised in line with the FEFO principle. Place products that will expire first in front of products with a later expiration date and issue stock accordingly to ensure products in use are not past their expiration date. Remember that the order in which products are received is not necessarily the order in which they will expire.	
ISO15189:2022 Clause 6.6.4; QMS 01, WHO 2013	
7.11 <u>Product Expiration</u> Are all reagents/test kits in use (and in stock) currently within the manufacturer-assigned expiration or within stability?	Score /2
Note 1: All reagents and test kits in use, as well as those in stock, should be within the manufacturer-assigned expiry dates.	
Note 2: Expired controls and calibrators must not be used.	
ISO15189:2022 Clause 6.6.5	
7.12 <u>Disposal of Expired Products</u> Are expired products labelled and disposed of properly?	Score /2
Note: Expired products should be disposed of properly and records maintained. If safe disposal is not available at the laboratory, the manufacturer/supplier should take back the expired stock at the time of their next delivery.	
ISO15189:2022 Clause 6.6.7	
SECTION 07: SUPPLIER AND INVEN	ITORY MANAGEMENT
/27	

SECTION 08: PROCESS MANGEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited i.e., make reference to documentation, equipment, personnel, etc.

RE	QUIREMENTS	Y/P/N/ NA	Comment	
Ha tha of a inc <i>Not</i> <i>Iab</i>	Procedure and/or Process for Continuity and Emergency Preparedness Planning (Contingency Plan) s the laboratory defined a procedure and/or process it addresses, but is not limited to, the following activities d measures to address and mitigate the consequences any event that leads to interruptions of services luding but not limited to: tes: Contingency plans should be periodically tested. Where the oratory uses another laboratory as a backup, the performance of back-up laboratory shall be regularly reviewed including numerical plans in the event of failure of the back-up laboratory. Personnel; Equipment breakdown;		Score	/3
C.	Power outages;			
d. e.	Stock outs of reagents and consumables; Fire, natural disasters, e.g., severe weather or floods, bomb threats or civil disturbances			
ISC	015189:2022 Clause 7.8; CLSI GP36-A			
8.2	Implementation of Continuity and Emergency Preparedness Planning		Score	/3
a.	Has laboratory management developed and implemented a continuity and emergency preparedness plan covering all laboratory operations (including inputs from risk assessments, internal audits, management reviews, safety audits, etc.			
No:	te: Reference CLSI GP36-A [35] Is the continuity and emergency preparedness plan periodically tested for its continued effectiveness and are actions taken to address any identified gaps?			
C.	Are there records of monitoring the effectiveness of the continuity and emergency preparedness plan?			
d.	Has the continuity and emergency preparedness plan been communicated and training provided to all relevant laboratory personnel?			
ISC	015189:2022 Clause 7.8			
Pro Ha tha	B <u>Procedure and/or Process for Pre-examination</u> <u>ocesses</u> s the laboratory defined a procedure and/or process it addresses, but is not limited to, the following?		Score	/3
info	te: The laboratory must have documented procedures and ormation for pre-examination activities to ensure the validity of results of examinations			
a.	Location(s) of the laboratory, operating hours, and contact information;			
	Procedures for requesting and collection of patient samples;			
C.	Instructions for collection activities (including sample, volume, and transportation requirements);			
d.	Instructions for pre-collection activities;			
e.	Preparation and storage prior to dispatch to the laboratory;			

f.	Scope of laboratory activities and time for expected	
g.	laboratory results; Time limits and special handling of patient samples;	
h.	Patient sample acceptance and rejection criteria;	
i.	Factors known to significantly impact the performance	e
	of examinations or interpretation of results;	
j.	Availability of advisory services;	
k.	Requirements for patient consent;	
١.	Ensuring patient confidentiality;	
m.	Complaints procedure.	
	15189:2022 Clause 7.2	
Are	 Instructions for Collection Activities e records available to show implementation of the owing: 	Score /3
a.	Verification of the identity of the patient from whom a primary sample is collected;	
b.	Verification and, when relevant, recording that the patient meets pre-examination requirements (e.g., fasting status, medication status [time of last dose, cessation], sample collection at predetermined time or time interval);	or land
C.	Collection of primary samples, with descriptions of the primary sample containers and any necessary additives, as well as the order of sample collection, where relevant;	e
	Labelling of primary samples in a manner that provides an unequivocal link with the patient from whom they are collected;	
e.	Recording of the identity of the person collecting the primary sample and the collection date, and, when relevant, recording of the collection time;	
f.	Requirements for separating or dividing the primary sample, when necessary;	
g.	Stabilisation and proper storage conditions before collected samples are delivered to the laboratory;	
h.	Safe disposal of materials used in the sample collection process.	
ISC	015189:2022 Clause 7.2.4.4	
	Test Request	Score /3
	es the laboratory adequately collect information needed examination performance?	∋d l
No: sha	te 1: Each request accepted by the laboratory for examination(s) Il be considered an agreement. The request may be paper-based electronic-based;	
rec	te 2: The review of service agreements occurs on sample eption. All portions of the primary sample must be equivocally traceable to the original primary sample.	
a.	Are all test requests accompanied by an acceptable and approved test requisition (e.g., a transmittal sheet/checklist/manifest/request form where applicable)?	
1	Does the request include patient identifiers, including	
b.	gender, date of birth, location of patient and unique identifier?	
b. c. d.	gender, date of birth, location of patient and unique	

e. Clinically relevant information;	
f. Date of sample collection (may include time where appropriate);	
g. Date and time of sample receipt (pre-analytical);	
h. Informed consent when required.	
ISO15189:2022 Clause 4.3 and Clause 7.2.4.4	
8.6 Primary Sample Receipt Procedure	Score /3
Does the laboratory implement the sample receipt procedures and are there records of implementation of the following:	
a. Unique patient identifier;	
 Are received samples evaluated according to acceptance and rejection criteria? 	
c. Are samples logged appropriately upon receipt in the laboratory (including date of receipt, time of receipt, and name of receiving personnel)?	
d. Are procedures in place to process 'urgent' samples?	
e. Are procedures in place to process oral requests?	
f. When samples are split, can the portions be traced back to the primary sample?	
g. Are samples delivered to the correct workstations as per the laboratory processes?	
ISO15189:2022 Clause 7.3.2 8.7 Pre-examination Handling, Processing and	
Prior to testing, are samples handled, processed, and stored according to specific sample type stability and testing requirements? Note: Samples should be stored under the appropriate conditions to maintain the stability of the sample according to international best practice and or testing guidelines.	
ISO15189:2022 Clause 7.2.7	· · · ·
8.8 <u>Sample Transportation</u> Note: All samples shall be transported to the laboratory in a manner that is safe to patients, users, personnel (including transporters), community and the environment. The laboratory must ensure that the samples were received within a temperature and time interval specified for sample collection.	Score /2
a. Are samples either received at the laboratory or referred to another site, packaged according to national guidelines/regulations?	
b. When specimens are transported across borders (i.e., internationally) is the packaging and transportation in full compliance with international (e.g., IATA) regulations?	
c. Are samples transported within acceptable timeframe and temperature intervals?	
d. Are specimens packaged according to national regulations when either received at the laboratory or referred to another site?	
ISO15189:2022 Clause 7.2.5	
8.9 <u>Procedure and/or Process for Referral</u> <u>Laboratories and Technical Consultants</u> Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?	Score /3
 Defining criteria for referral laboratories and technical consultants; 	

b. Selection and approval of referral laboratories;	
 Technical consultants who provide advice and interpretation; 	
 Evaluation and monitoring of the performance of referral laboratories and technical consultants; 	
e. Maintenance of a list of approved referral laboratories and technical consultants;	
f. Maintenance of records of referred samples;	
g. Tracking of referred samples and their results;	
h. Reporting of results from referral laboratories;	
 Management of critical results received from referral laboratories; 	
j. Packaging and transportation of referred samples;	
 Record of communication of results from referral laboratories and technical consultants. 	
ISO15189:2022 Clause 6.8.2	
8.10 <u>Referral Laboratories and Technical Consultants</u>	Score /2
Note: The laboratory must have systems in place to ensure that the referral laboratories are competent to perform the services required. Evaluations may be in the form of checking their accreditation status, using a questionnaire, performing audits, use of blinded samples, etc.	
a. Does the laboratory select referral laboratories and technical consultants based on specific criteria?	
b. Are there documented reviews and evaluations of referral laboratories and technical consultants as defined by the laboratory?	
c. Is there a register of referral laboratories and technical consultants?	
d. Are referred samples tracked properly using a logbook, tracking form or electronically?	
e. Does the laboratory ensure that the results obtained by the referral laboratory are tracked to ensure timely delivery to the user?	
ISO15189:2022 Clause 6.8.2	
 8.11 Procedure and/or Process for Documentation of Examination Procedures Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? 	Score /2
Note: Working instructions, job aids, flow process diagrams or similar systems that summarise key information are acceptable for use as a quick reference at the workbench, provided that a fully documented examination procedure (e.g., SOP) is available for reference. Information from product instructions for use can be incorporated into examination procedures by reference in the SOP.	
 Defining the format, language, and appropriate location of examination procedures; 	
b. Selection and approval of referral laboratories.	
ISO15189:2022 Clause 7.3.6	
8.12 Location of Examination Procedures	Score /2
Are examination information and instructions available in appropriate locations?	
Note: Examination information and instructions may include SOPs, package inserts, user manuals, job aids, etc.	
ISO15189:2022 Clause 7.3.6	

8.13 Reagents and Consumables Acceptance Testing	Score /2
Is verification performed and documented before use for	
each new preparation, new lot, and new shipment of	
reagents and consumables?	
Note: Verification can be in-house or based on the Certificate of	
Analysis of the reagent.	
ISO15189:2022 Clause 6.6.3	
8.14 Procedure and/or Process for Internal Quality	Score /3
Control (IQC)	Score 73
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
Note: The laboratory should choose concentrations of control	
materials, wherever possible, especially at or near clinical decision	
values, which ensure the validity of decisions made. Use of	
independent third-party control materials should be considered,	
either instead of, or in addition to, any control materials supplied by	
the reagent or instrument manufacturer.	
a. Definition of IQC criteria (acceptance and rejection);	
b. Frequency of processing IQC;	
c. Definition of acceptable ranges (package inserts or in	
house);	<u> </u>
d. Use of alternate quality control methods when	
appropriate quality controls are not available (in-house	
produced IQC materials, EQA materials, etc.);	
e. Recording, evaluating, and monitoring ongoing IQC	
performance;	
f. Troubleshooting unacceptable IQC performance.	
ISO15189:2022 Clause 7.3.7	
8.15 Quality Control	Score /3
a. Is internal quality control performed and verified to be	
within acceptable limits before testing and release of	
results?	
b. Is corrective action taken and documented when	
quality control results fall outside the acceptable range	
and reviews identify non-conformities in a timely	
manner?	
c. Does the laboratory evaluate the results from patient	
samples that were examined after the last successful	
quality control result in the event of a quality control	
failure?	
ISO15189:2022 Clause 7.3.7.2	
8.16 Monitoring of Quality Control Performance	Score /3
and monitoring of educity control i chomance	
a. Are quality control results monitored and reviewed to	
assess the performance of the method and/or identify	
errors over time for quantitative tests?	
Note Manifestary of small (
Note: Monitoring of quality controls can include biases, trends, and Levy-Jennings charts.	
b. Is appropriate action taken and documented when	
there is an error or rule violation with the quality	
control results?	
Noto: The laboratory must desumant and implement a system it	
Note: The laboratory must document and implement a system it would use to evaluate patient results since the last successful	
quality control. The evaluation could be done by re-examining selected samples of various batches or re-examining samples as	
quality control. The evaluation could be done by re-examining	
quality control. The evaluation could be done by re-examining selected samples of various batches or re-examining samples as	

8.17 <u>Comparability of Examination Results</u>	Score /2
Does the laboratory compare results to ensure there is no clinically significant variation when the same test for a	
patient sample is performed with different methods or	
equipment, including POCT?	
Note: The laboratory should document and implement a system to ensure there is comparability of results. This could be done using	
EQA performance, using blinded samples, and parallel testing.a. Does the laboratory record the results of comparability	
performed and its acceptability?	
b. Does the laboratory periodically review the comparability of results?	
c. Does the laboratory evaluate and act upon the impact	
of any differences on biological reference intervals and	
clinical decision limits?	
d. Does the laboratory inform users of any clinically significant differences in comparability of results?	
ISO15189:2022 Clause 7.3.7.4	· · ·
8.18 Monitoring and Recording Environmental	Score /2
Conditions	
Are the following environmental conditions monitored and recorded daily?	
Note: The laboratory shall monitor, control, and record	
environmental conditions, as required by relevant specifications or	
where it may influence the quality of the sample, results, and/or the safety of patients, visitors, laboratory users, and personnel.	
a. Room temperatures, including storage areas and all areas involved with testing, e.g., server rooms;	
b. Freezers;	
c. Refrigerators;	
d. Incubators;	
e. Water baths.	
ISO15189:2022 Clause 6.3	
8.19 <u>Reviewing of Environmental Conditions</u>	Score /2
a. Have acceptable ranges been defined for all environmental conditions?	
b. Is there evidence of documentation for action taken in response to unacceptable conditions?	
· · ·	
ISO15189:2022 Clause 6.3	Coore (2)
8.20 <u>Procedure and/or Process for External Quality</u> Assessment (EQA)	Score /3
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
Note: EQA should cover the pre-examination process, examination	
process and post-examination process. Where an EQA programme	
is not available, the laboratory can use alternative methods with clearly defined acceptable results, e.g., exchange of samples with	
other laboratories, testing certified materials, EQA samples	
previously tested. All procedures or equipment used as backup must also be included in the EQA programme.	
a. All examinations, including POCT, must be enrolled in	
EQA or alternative methods, in the event EQA is not available;	
b. Defining EQA processing criteria (treating EQA as	
,	

e. Use of alternate approaches when the EQA programme is not available (e.g., reference materials, blind testing, etc.); Recording, evaluating, and monitoring ongoing EQA performance; g. Troubleshooting unacceptable EQA performance. IS015189:2022 Clause 7.3.7 8.21 Participation in External Quality Assessment (EQA) Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; • Interlaboratory comparisons of results of examinations of identical ICC material, analysis of a different to number of the manufacturer's end-user calibrator or the manufacturer's truenees control material; • Analysis of reference materials considered to be commutable with patient samples y to tast two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least so of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? c. Is the EQA or AAP performance? c. Is corrective action documented fo	.g., reference materials,	
blind testing, etc.); Image: Control of the second sec	-	
f. Recording, evaluating, and monitoring ongoing EQA performance; g. Troubleshooting unacceptable EQA performance. IS015189:2022 Clause 7.3.7 Score Sc21 Participation in External Quality Assessment (EQA) Score (EQA) Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Score Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; • Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of alforent tot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; • • Analysis of microbiological organisms using split / blind testing of the same sample by at least two methods; • • Analysis of aditerent correlation studies; • • Analysis of aditerent correlation studies; • • Analysis of materials come from providers who are approved suppliers? • • Analysis of aditent aspecimens? • • Analysis of aditent aspecimens? • • Analysis of aditent aspecimens? • • <	EQA performance. Quality Assessment Score EQA or external s (APP) for all tests? : with other laboratories; ults of examinations of uates individual laboratory from participants using the fferent tot number of the or the manufacturer's sms using split / blind asst two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
gerformance; g. Troubleshooting unacceptable EQA performance. ISO15189:2022 Clause 7.3.7 Score Score ISO15189:2022 Clause 7.3.7 Score ISO15189:2022 Clause 7.3.7 Score ISO15189:2022 Clause 7.3.7 Score Score ISO1518:2022 Clause 7.3.7 Score Score ISO161 Clause Assessment ISO22 Clause 7.3.7 Score of the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note: Scoppies alternatives include: Interbaloratory comparisons of results of examinations of ident to be commutable with patient samples; or or bid tesor ider of to be commutable with patient samples; or bid	EQA performance. Quality Assessment EQA or external s (APP) for all tests? : with other laboratories; ults of examinations of uates individual laboratory from participants using the fferent tot number of the or the manufacturer's sms using split / blind asst two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
g. Troubleshooting unacceptable EQA performance. ISO15189:2022 Clause 7.3.7 8.21 Participation in External Quality Assessment (EQA) Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: Participation in sample exchanges with other laboratories; Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against from participants using the same IQC material, analysis of a different to number of the manufacture's end-user calibrator or the manufacturer's trueness control material; • Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers? • Analysis of materials comsidered to be commutable with patient samples; • Analysis of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is cort cause analysis performed for unacceptable EQA or AAP performance? e. <td>Quality Assessment Score /3 EQA or external s (APP) for all tests? . . with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent to number of the or the manufacturer's . . sms using split / blind ast two persons, or on at wo methods; isidered to be commutable . . . linical correlation studies; tissue repositories. he from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ad for unacceptable </td> <td>Score /3 </td>	Quality Assessment Score /3 EQA or external s (APP) for all tests? . . with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent to number of the or the manufacturer's . . sms using split / blind ast two persons, or on at wo methods; isidered to be commutable . . . linical correlation studies; tissue repositories. he from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ad for unacceptable 	Score /3
SO15189:2022 Clause 7.3.7 8.21 Participation in External Quality Assessment (EQA) Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; • Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different tot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of patient samples from clinical correlation studies; • Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is cort cause analysis performed for unacceptable EQA or AAP performance?	Quality Assessment Score /3 EQA or external s (APP) for all tests? . . with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent to number of the or the manufacturer's . . sms using split / blind ast two persons, or on at wo methods; isidered to be commutable . . . linical correlation studies; tissue repositories. he from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ad for unacceptable 	Score /3
8.21 Participation in External Quality Assessment (EQA) Score Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; Interlaboratory comparisons of results of examinations of identicial. Which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different to number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two methods; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of materials from cell and tissue repositories. • Do EQA or AAP materials come from providers who are approved suppliers? • Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is corrective action documented for unacceptable EQA or AAP performance?	EQA or external s (APP) for all tests? : with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent lot number of the or the manufacturer's sms using split / blind asst two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. he from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	Score /3
Image: Control of the second secon	EQA or external s (APP) for all tests? : with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent lot number of the or the manufacturer's sms using split / blind asst two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. he from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	Score /3
Does the laboratory participate in EQA or external alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; • Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results gainst pooled results from participants using the same IQC material, analysis of a different tot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; • Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	s (APP) for all tests? : with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; tissue repositories. he from providers who e laboratory, relevant holled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable EQA	
alternative assessment procedures (APP) for all tests? Note 1: Acceptable alternatives include: • Participation in sample exchanges with other laboratories; • Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different to number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; • Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA e. No crucive action documented for unacceptable EQA	s (APP) for all tests? : with other laboratories; uits of examinations of uates individual laboratory from participants using the fferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; tissue repositories. he from providers who e laboratory, relevant holled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable EQA	
Note 1: Acceptable alternatives include: Participation in sample exchanges with other laboratories; Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different lot number of the manufacturer's end-user calibrator or the manufacturer's of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two persons, or on at least two materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for u	with other laboratories; uits of examinations of uates individual laboratory from participants using the ferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. the from providers who e laboratory, relevant indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable EQA	
 Participation in sample exchanges with other laboratories; Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different lot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; Analysis of patient samples from clinical correlation studies; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. 	with other laboratories; uits of examinations of uates individual laboratory for unations of for participants using the fferent lot number of the or the manufacturer's ssms using split / blind ast two persons, or on at wo methods; nsidered to be commutable inical correlation studies; tissue repositories. inical correlation studies; total correlation studies; inical correlation studies; total correlation studies; inical correlati	
 Interlaboratory comparisons of results of examinations of identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different lot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of reference materials correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ults of examinations of uates individual laboratory from participants using the fferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
identical IQC materials, which evaluates individual laboratory IQC results against pooled results from participants using the same IQC material, analysis of a different lot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysers, or by at least two thods; Analysis of patient samples from clinical correlation studies; Analysis of patient samples from clinical correlation studies; Analysis of patient samples from clinical correlation studies; Analysis of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	uates individual laboratory from participants using the fiferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable linical correlation studies; itissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
same IQC material, analysis of a different lot number of the manufacturer's end-user calibrator or the manufacturer's trueness control material; • Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two persons, or on at least two analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ferent lot number of the or the manufacturer's sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. inical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
manufacturer's end-user calibrator or the manufacturer's trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ror the manufacturer's sims using split / blind ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
trueness control material; Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable Inicial correlation studies; tissue repositories. linical correlation studies; tissue repositories. Inicial correlation studies; tissue repositories. ne from providers who e laboratory, relevant Inicial correlation studies; tissue repositories. ndled and tested the pecimens? Inicial correlation studies; tissue repositories. ce of the laboratory elevant personnel? Inicial correlation studies; tissue repositories. ce of the laboratory elevant personnel? Inicial correlation studies; tissue repositories. ed for unacceptable Inicial correlation studies; tissue repositories.	
testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; it issue repositories. In e from providers who e laboratory, relevant indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
 Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	Inical correlation studies; tissue repositories. Ine from providers who e laboratory, relevant Indled and tested the pecimens? Ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	tissue repositories.	
a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ne from providers who	
are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	e laboratory, relevant Image: Constraint of the sted the pecimens? indled and tested the pecimens? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens?	
are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	e laboratory, relevant Image: Constraint of the sted the pecimens? indled and tested the pecimens? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens?	
are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	e laboratory, relevant Image: Constraint of the sted the pecimens? indled and tested the pecimens? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens? ice of the laboratory elevant personnel? Image: Constraint of the sted the pecimens? ice of for unacceptable Image: Constraint of the sted the pecimens?	
Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	Indied and tested the pecimens? Image: ce of the laboratory relevant personnel? relevant personnel? red for unacceptable red for unacceptable EQA	
Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	Indied and tested the pecimens? Image: ce of the laboratory relevant personnel? relevant personnel? red for unacceptable red for unacceptable EQA	
 b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	pecimens? ce of the laboratory relevant personnel? ed for unacceptable ed for unacceptable EQA	
same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	pecimens? ce of the laboratory relevant personnel? ed for unacceptable ed for unacceptable EQA	
 c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	ed for unacceptable EQA	
reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	elevant personnel? ed for unacceptable ed for unacceptable EQA	
d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ed for unacceptable EQA	
EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ed for unacceptable EQA	
e. Is corrective action documented for unacceptable EQA		
or AAP performance?	alyse, review and report	
	alyse, review and report	1 1
	alyse, review and report	
Note: The laboratory should handle, analyse, review and report		
EQA or AAP should be documented. Acceptable results showing		
	cceptable results showing	
ISO15189:2022 Clause 7.3.7	cceptable results showing	
8.22 Procedure and/or Process for Verification and Score	cceptable results showing should also be investigated.	
Validation of Examinations Methods	cceptable results showing should also be investigated.	Score /3
Has the laboratory defined a procedure and/or process	cceptable results showing should also be investigated. a for Verification and ns Methods	Score /3
	Score table results showing should also be investigated. S for Verification and Is Methods edure and/or process	Score /3
וומו מעמיפסספס, שער וס ווטר וווווונכע נט, נווכ וטווטשווע י	Score table results showing should also be investigated. S for Verification and Is Methods edure and/or process	Score /3
Note 1: Validations should be done on a) non-standard methods, b)	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process o, the following?	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) rods, c) standard methods alidated methods wethods that are being used	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) rods, c) standard methods alidated methods ethods that are being used rest of evaluating of whether	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) ods, c) standard methods alidated methods ethods that are being used ress of evaluating of whether characteristics stated by the	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the manufacturer, i.e., the manufacturer's validation claims. The performance characteristics are obtained from the manufacturer	cceptable results showing should also be investigated. S for Verification and hs Methods edure and/or process o, the following? a) non-standard methods, b) pods, c) standard methods alidated methods wethods that are being used cess of evaluating of whether characteristics stated by the validation claims. The ed from the manufacturer	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the manufacturer, i.e., the manufacturer's validation claims. The performance characteristics are obtained from the manufacturer (validation reports) or from package inserts. Comparison of	cceptable results showing should also be investigated. a for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) pods, c) standard methods alidated methods wethods that are being used cess of evaluating of whether characteristics stated by the validation claims. The ed from the manufacturer serts. Comparison of	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the manufacturer, i.e., the manufacturer's validation claims. The performance characteristics are obtained from the manufacturer (validation reports) or from package inserts. Comparison of different methods used for same tests is ongoing verification. The	cceptable results showing should also be investigated. a for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) rods, c) standard methods alidated methods alidated methods ethods that are being used cess of evaluating of whether characteristics stated by the validation claims. The ed from the manufacturer serts. Comparison of is ongoing verification. The	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified. Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the manufacturer, i.e., the manufacturer's validation claims. The performance characteristics are obtained from the manufacturer (validation reports) or from package inserts. Comparison of	cceptable results showing should also be investigated. a for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) rods, c) standard methods alidated methods alidated methods ethods that are being used cess of evaluating of whether characteristics stated by the validation claims. The ed from the manufacturer serts. Comparison of is ongoing verification. The	Score /3
Investigation and correction of problems identified by unacceptable	ns identified by unacceptable	
	cceptable results showing	
ISO15189:2022 Clause 7.3.7	cceptable results showing	
8.22 Procedure and/or Process for Verification and	cceptable results showing	
8.22 Procedure and/or Process for Verification and Score	cceptable results showing	
	cceptable results showing should also be investigated.	Score /3
	cceptable results showing should also be investigated. Se for Verification and Score /3	Score /3
Has the laboratory defined a procedure and/or process	cceptable results showing should also be investigated. So for Verification and Score /3	Score /3
	cceptable results showing should also be investigated. <u>a for Verification and</u> <u>hs Methods</u>	Score /3
that addresses, but is not limited to, the following?	cceptable results showing should also be investigated. <u>a for Verification and</u> <u>hs Methods</u>	Score /3
that addresses but is not limited to the following?	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process	Score /3
	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process	Score /3
	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process	Score /3
	Score table results showing should also be investigated. S for Verification and Is Methods edure and/or process	Score /3
נומו מעמיפסספס, שעו זס דוטר ווודוונכע נט, נוופ וטווטשוועץ י	Score table results showing should also be investigated. S for Verification and Is Methods edure and/or process	Score /3
	Score solution Score /3 S for Verification and ins Methods Score /3 edure and/or process o, the following? Image: Score solution in the following instruction in the fol	Score /3
	Score solution Score /3 S for Verification and ins Methods Score /3 edure and/or process o, the following? Image: Score solution in the following instruction in the fol	Score /3
	Score solution Score /3 S for Verification and ins Methods Score /3 edure and/or process o, the following? Image: Score solution in the following instruction in the fol	Score /3
Note 1: Validations should be done on a) non-standard methods, b)	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b)	Score /3
Note 1: Validations should be done on a) non-standard methods, b)	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b)	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. c for Verification and ns Methods ns Methods edure and/or process o, the following? a) non-standard methods, b) oods, c) standard methods alidated methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. c for Verification and ns Methods ns Methods edure and/or process o, the following? a) non-standard methods, b) oods, c) standard methods alidated methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. c for Verification and ns Methods edure and/or process o, the following? a) non-standard methods, b) odds, c) standard methods alidated methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. c for Verification and ns Methods ns Methods edure and/or process o, the following? a) non-standard methods, b) odds, c) standard methods alidated methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods subsequently modified.	cceptable results showing should also be investigated. should also be investing also be investigated.	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods used outside their intended scope, d) validated methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b) laboratory designed or developed methods, c) standard methods	cceptable results showing should also be investigated. a for Verification and as for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b) mods, c) standard methods	Score /3
Note 1: Validations should be done on a) non-standard methods, b)	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b)	Score /3
Note 1: Validations should be done on a) non-standard methods, b)	cceptable results showing should also be investigated. a for Verification and as Methods edure and/or process o, the following? a) non-standard methods, b)	Score /3
	cceptable results showing should also be investigated. s for Verification and ns Methods edure and/or process o, the following?	Score /3
	should also be investigated. So for Verification and Score in Scor	Score /
EQA or AAP should be documented. Acceptable results showing bias or trends suggest that a problem should also be investigated.		
or AAP performance?	alyse, review and report	
e. Is corrective action documented for unacceptable EQA		
e. Is corrective action documented for unacceptable EQA		
EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ed for unacceptable EQA	
d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ed for unacceptable EQA	
reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	elevant personnel? ed for unacceptable ed for unacceptable EQA	
 c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	ed for unacceptable EQA	
 c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	ed for unacceptable EQA	
same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	pecimens? ce of the laboratory relevant personnel? ed for unacceptable ed for unacceptable EQA	
Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	Indled and tested the pecimens? Image: ce of the laboratory relevant personnel? relevant personnel? red for unacceptable	
Note: Suppliers may be approved by the laboratory, relevant Image: Suppliers may be approved by the laboratory, relevant b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? Image: Suppliers may be approved by the laboratory c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? Image: Suppliers may be approved by the laboratory d. Is root cause analysis performed for unacceptable EQA or AAP performance? Image: Suppliers may be approved by the laboratory e. Is corrective action documented for unacceptable EQA Image: Suppliers may be approved by the laboratory	Indled and tested the pecimens? Image: ce of the laboratory relevant personnel? relevant personnel? red for unacceptable	
are approved suppliers?Image: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons.b. Are EQA or AAP materials handled and tested the same way as routine patient specimens?Image: Suppliers may be approved by the laboratory reviewed and discussed with relevant personnel?c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel?Image: Suppliers may be approved by the laboratory reviewed and discussed with relevant personnel?d. Is root cause analysis performed for unacceptable EQA or AAP performance?Image: Suppliers may be approved by the laboratory reviewed and discussed with relevant personnel?e. Is corrective action documented for unacceptable EQAImage: Suppliers may be approved by the laboratory may be approved by the laboratory reviewed and discussed with relevant personnel?	e laboratory, relevant Indied and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
a. Do EQA or AAP materials come from providers who are approved suppliers? Image: Complete Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? Image: Complete Suppliers may be approved by the laboratory reviewed and discussed with relevant personnel? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? Image: Complete Suppliers Performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? Image: Complete Suppliers Performance? e. Is corrective action documented for unacceptable EQA Image: Complete Suppliers Performance Perform	ne from providers who	
Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	tissue repositories. he from providers who e laboratory, relevant hdled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
 Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	tissue repositories. he from providers who e laboratory, relevant hdled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
 Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	Inicial correlation studies; tissue repositories. Ine from providers who e laboratory, relevant Indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
 Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	Inicial correlation studies; tissue repositories. Ine from providers who e laboratory, relevant Indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
 Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	Inicial correlation studies; tissue repositories. Ine from providers who e laboratory, relevant Indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable	
least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; • Analysis of reference materials considered to be commutable with patient samples; • Analysis of patient samples from clinical correlation studies; • Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA	ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
 Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods; Analysis of reference materials considered to be commutable with patient samples; Analysis of patient samples from clinical correlation studies; Analysis of materials from cell and tissue repositories. a. Do EQA or AAP materials come from providers who are approved suppliers? Note: Suppliers may be approved by the laboratory, relevant Ministry, or authorised persons. b. Are EQA or AAP materials handled and tested the same way as routine patient specimens? c. Is the EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel? d. Is root cause analysis performed for unacceptable EQA or AAP performance? e. Is corrective action documented for unacceptable EQA 	ast two persons, or on at wo methods; insidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant indled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	
trueness control material;Analysis of microbiological organisms using split / blind testing of the same sample by at least two persons, or on at least two analysers, or by at least two methods;Analysis of reference materials considered to be commutable with patient samples;Analysis of reference materials considered to be commutable with patient samples;Analysis of patient samples from clinical correlation studies;Analysis of materials from cell and tissue repositories.Analysis of materials from cell and tissue repositories.a. Do EQA or AAP materials come from providers who are approved suppliers?Analysis of authorised persons.b. Are EQA or AAP materials handled and tested the same way as routine patient specimens?Endotation succeptable EQA or AAP performance of the laboratory reviewed and discussed with relevant personnel?d. Is root cause analysis performed for unacceptable EQA or AAP performance?Endotation succeptable EQA or AAP performance?	sms using split / blind ast two persons, or on at wo methods; nsidered to be commutable linical correlation studies; tissue repositories. ne from providers who e laboratory, relevant ndled and tested the pecimens? ce of the laboratory elevant personnel? ed for unacceptable ed for unacceptable EQA	

Note 3: All procedures or equipment used as backup must also be validated/verified as relevant.	
a. Defining the validation or verification protocol	
(including the authorisation for the intended use);	
b. Performing method validation or verification;	
c. Defining validation or verification report.	
ISO15189:2022 Clause 7.3.2 and Clause 7.3.3	
8.23 <u>Records of Verification of Examination Methods</u>	Score /3
Note 1: Newly introduced methods must be verified onsite to ensure that their introduction yields performance equal to or better than the manufacturer's claims/specifications.	
Note 2: 'Verification' is performed on methods that are being used without any modifications and is a process of evaluating of whether the procedure meets the performance characteristics stated by the manufacturer, i.e., the manufacturer's validation claims. The performance characteristics are obtained from the manufacturer (validation reports) or from package inserts. Comparison of different methods used for same tests is ongoing verification.	
a. Has the laboratory developed, reviewed, and	
approved the verification plan (protocol) for each testing method in use prior to verification?	
b. Has the laboratory defined a verification report?	
c. Has the verification report been reviewed by an authorised person?	
d. Has the laboratory generated, reviewed, and approved the verification report for each testing method in use?	
e. Are verification records available (including raw data, calculations, etc.)?	
ISO15189:2022 Clause 7.3.2	
8.24 <u>Records of Validation of Examination Methods</u> Note: Validations should be done on a) non-standard methods, b) laboratory-designed or -developed methods, c) standard methods	Score /3
used outside their intended scope, d) validated methods subsequently modified.	
a. Has the laboratory developed, reviewed, and	
approved the validation plan (protocol) for each testing	
method in use prior to validation?b. Has the laboratory generated, reviewed, and approved	+ +
the validation report for each testing method in use?	
c. Are validation records available (including raw data, calculations, etc.)?	
ISO15189:2022 Clause 7.3.3	

8.25 Procedure and/or Process for Measurement	Score /2
Uncertainty (MU)	
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
Note: MU is used to indicate the confidence we have that the	
reported figure is correct. MU may be calculated using the	
calculated coefficient of variation (CV) of at least 30 sets of internal	
precision quality control data: CV% x 2 = MU.	
a. Determining MU (analytical error) on measured	
quantity values (quantitative tests);	
b. Defining performance requirements for MU.	
ISO15189:2022 Clause 7.3.4; ISO/TS 20914:2019	
8.26 Measurement Uncertainty of Measured	Score /3
Quantitative Tests	
Does the laboratory have documented estimates of MU	
for each semi-quantitative and quantitative test in use?	
Note: MU should be calculated at different clinical decision limits.	
Cumulative IQC (minimum 6 months data) may be used to calculate	
MU.	
a. Has the laboratory calculated MU for each quantitative	
test in use?	
Note: If quantitative values are used to decide a qualitative result,	
then MU must be performed.	
b. Has the laboratory defined the performance	
requirements (factors that affect MU) for the MU of	
each measurement examination and does the	
laboratory regularly review estimates of MU?	
c. Does the laboratory make its calculated MU available	
to its users upon request?	
d. Does the laboratory document reasons for exclusion	
from MU estimation for examination procedures where	
evaluation of MU is not possible or relevant?	
ISO15189:2022 Clause 7.3.4	· · · · · ·
8.27 Procedure and/or Process for Biological	Score /3
Reference Intervals or Clinical Decision Limits	
Has the laboratory defined a procedure and/or process	
that addresses, but is not limited to, the following?	
Nata. The laboratory about define the biological references intervale	
Note: The laboratory shall define the biological reference intervals or clinical decision values, document the basis for the reference	
intervals or decision values and communicate this information to	
users.	
a. Defining biological reference intervals or clinical	
decision limits;	
b. Biological reference intervals for examinations that	
identify presence or absence of a characteristic;	
c. Source of reference intervals or clinical decision limits;	
 d. Communication of changes of biological reference 	
intervals or clinical decision limits to users.	
ISO15189:2022 Clause 7.3.5	
SECTION 08: PROCESS MANAGEM	MENT /71

Page 38 of 55

SECTION 09: INFORMATION MANAGEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited i.e., make reference to documentation, equipment, personnel, etc.

REQUIREMENTS	Y/P/N/ NA	Comment		
9.1 Procedure and/or Process for Reporting and			Score	/3
Release of Results Has the laboratory defined a procedure and/or process				
that addresses, but is not limited to, the following?				
a. Defining report format;				
b. Medium (electronic or paper based);				
c. Reviewing of patient results;				
 Communication of alert, urgent and critical patient results; 				
e. Release of results and reports by authorised persons;				
f. Amendments of results and reports;				
g. Issue of amended reports;				
h. Reporting of results performed by a referral laboratory;				
i. Identification of the referral laboratory;				
j. Retention and maintenance of patient results.				
ISO15189:2022 Clause 7.4.1	L			
9.2 <u>Test Result Reporting System</u> Are test results legible, technically verified, and confirmed against patient identity?			Score	/2
Note: Paper-based reports must be written in ink and have documentation of review and verification. Evidence of documentation of verification must be available.				
ISO15189:2022 7.4.1				
9.3 <u>Testing Personnel</u> Is the person authorizing the release of the result identified on the result report or other records (paper- or electronic-based)?			Score	/2
ISO15189:2022 Clause 7.4.1.2				
9.4 <u>Requirements for Reports</u> Does the laboratory report contain at least the following:			Score	/3
 Clear, unambiguous identification of the examinations performed (including POCT reports); 				
b. Identification of the laboratory issuing the report;				
 Identification of all examinations performed by a referral laboratory or part of a research or development program; 				
 Patient identification, location, date of primary sample collection (and time, relevant to patient care), date of issue on every page of the report; 				
e. Name of the requester (user);				
 Identification of examination method used, where relevant, and including, where possible and necessary, harmonised (electronic) identification of the measurand and measurement principle; 				
 Type of primary sample and any specific information necessary to describe the sample; 				
Note: (e.g., source, site of sample, macroscopic description, etc.)				
h. Provisional reports;				
i. Reporting of result in SI units, when applicable;				

 Biological reference intervals, clinical decision limits, likelihood ratios; 	
k. Presence of space for interpretation or comments of	
results, when applicable;	
I. Indication of critical results;	
 Identification of the person(s) reviewing and authorizing the release of the report; 	
n. Date and time of the report;	
 Page number to total number of pages (e.g., 'Page 1 of 5'); 	
p. Clear identification of revisions, including reference to the date and patient identity on the original report, and user notification of the revision, when issuing revised	
 reports; q. Revised record shows time and date of change and name of the person responsible for the change; 	
Note: When the reporting system cannot capture amendments, changes or alterations, a record of such shall be kept.	
r. Does the original report entry remain in the record?	
Note: Applicable to paper- and electronic-based systems.	
ISO15189:2022 Clause 7.4.1.6	
9.5 <u>Analytic System / Method Tracing</u> Are test results traceable to the equipment used for testing when more than one instrument is in use for the same test?	Score /2
Note: There must be traceability of sample results, including proficiency testing results, to a specific analytical system or method.	
ISO15189:2022 Clause 7.3.7.4, Clause 7.4.1.3 and Clause 7.4.1.4	
	0
9.6 <u>Procedure and/or Process for Laboratory</u> <u>Information System (LIS) (computerised or non-</u> <u>computerised)</u> Has the laboratory defined a procedure and/or process	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; c. Patient confidentiality; 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; c. Patient confidentiality; d. Maintenance and troubleshooting of the LIS; e. Back-up and storage of non-computerised system; f. Ongoing checks of calculations used to generate 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; c. Patient confidentiality; d. Maintenance and troubleshooting of the LIS; e. Back-up and storage of non-computerised system; f. Ongoing checks of calculations used to generate results; g. Data transfers checks (interface between testing systems and LIS) for protection and security of the system against external and internal access and tampering; 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; c. Patient confidentiality; d. Maintenance and troubleshooting of the LIS; e. Back-up and storage of non-computerised system; f. Ongoing checks of calculations used to generate results; g. Data transfers checks (interface between testing systems and LIS) for protection and security of the system against external and internal access and 	Score /3
 9.6 Procedure and/or Process for Laboratory Information System (LIS) (computerised or non- computerised) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: 'Information systems' includes the management of data and information contained in both computer and non-computerised systems. Some of the requirements may be more applicable to computer systems than to non-computerised systems. Computerised systems can include those integral to the functioning of laboratory equipment and stand-alone systems using generic software, such as word processing, spreadsheet and database applications that generate, collate, report and archive patient information and reports. a. Verification of the LIS on installation and after every upgrade; b. Definition of authorities and responsibilities for management and use of the LIS; c. Patient confidentiality; d. Maintenance and troubleshooting of the LIS; e. Back-up and storage of non-computerised system; f. Ongoing checks of calculations used to generate results; g. Data transfers checks (interface between testing systems and LIS) for protection and security of the system against external and internal access and tampering; h. Automated selection, review, release, and reporting of 	Score /3

9.7 Archived Data Laboratory and Storage	Score /2
Are archived results (paper or data-storage media)	
properly labelled and stored in a secure location	
accessible only to authorised personnel?	
Note: All patient data, paper, and external storage devices must be	
retained as per the laboratory's retention policy and should be stored in a safe and access-controlled environment.	
ISO15189:2022 Clause 8.4.3	
	Secret 12
9.8 <u>Authorities and Responsibilities for Information</u> Management	Score /2
Has the laboratory designated authorities and	
responsibilities for the management and use of the LIS,	
both paper- and electronic-based, including access,	
maintenance and modifications that may affect patient	
care?	
Note 1. (Information systems' includes the monorement of data and	
Note 1: 'Information systems' includes the management of data and information contained in both computer and non-computerised	
systems. Some of the requirements may be more applicable to	
computer systems than to non-computerised systems.	
Computerised systems can include those integral to the functioning of laboratory equipment and standalone systems using generic	
software, such as word processing, spreadsheet and database	
applications that generate, collate, report and archive patient information and reports."	
Note 2: Authorities and responsibilities may be defined in the	
authority matrix, job description, etc. Is the following in place and implemented?	
a. Controlled access to patient data and information;	
b. Controlled access to enter patient data and examination results;	
c. Controlled access to modifying patient data or	
examination results;	
 Controlled access to the release of examination results and reports. 	
ISO15189:2022 Clause 7.6.2	
9.9 Verification of Electronic Laboratory Information	Score /2
System	
Note: The laboratory must perform verification of the system after upgrades and to ensure previously stored patient results have not been affected.	
a. Has the system been validated and or verified before	
implementation and version upgrades?	
b. Are ongoing system checks available for correct	
transmission, calculation and storage of results and	
records?	
c. Are there records to check the functioning of the	
interface of the LIS to other systems (e.g., analyser's,	
hospital information system)?	
ISO15189:2022 Clause 7.6.3	
9.10 <u>Records of Maintenance of the Laboratory</u>	Score /3
Information System	
Note 1: If the LIS is maintained offsite, records of maintenance must	
be readily available. The laboratory should include the LIS as part of	
their internal audit.	
a. Records of regular service by authorised and trained	
personnel; b Records of system failures with documented	
b. Records of system failures with documented	
annonriate root cause analysis corrective actions and	
appropriate root cause analysis, corrective actions and verification:	
verification;	

SECTION 09: INFORMATION MANA	GEMENT	/24
ISO15189:2022 Clause 7.6.3		
Note: If the LIS is maintained offsite, records of maintenance must be readily available. The laboratory should include the LIS as part of their internal audit.		
 Evidence that the laboratory has implemented a process to ensure the protection and security of the LIS 		

SECTION 10: NONCONFORMIN	IG E\	/ENT MANAGEMENT
For each question, please indicate as relevant, Yes (Y), Partial (P), No (N satisfactorily present to indicate Yes (Y). Provide comments for each Pa may also provide information on what was audited i.e., make reference to	rtial (P), No	(N) or Not Applicable (NA). In the comment field you
REQUIREMENTS	Y/P/N/ NA	Comment
10.1 Procedure and/or Process for Handling of Nonconforming Work, Nonconformities and Corrective Action Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? a. Identification of nonconforming work and		Score /3
nonconformities in any aspect of the laboratory management system;		
 b. Documentation of nonconforming work and nonconformities; 		
c. Determination of level of risk and evaluation of the impact;d. Performing root cause analysis;		
d. Performing root cause analysis;e. Determination of the need for corrective action (how		
 and where); f. Assignment of roles and responsibilities for recalling, resolving and resumption of the nonconforming work 		
and nonconformities; g. Determining time frame for resolving nonconforming work and nonconformities;		
 Implementation of corrective action (including halting examinations and recalling of released results, where applicable); 		
i. Monitoring, reviewing and evaluating the effectiveness of the corrective action taken;		
j. Retention of records of nonconforming work and nonconformities.		
ISO15189:2022 Clause 7.5 and Clause 8.7		
10.2 Identification and Management of Nonconforming Work and Nonconformities		Score /3
Note: Nonconformities should be identified and managed in any aspect of the laboratory management system, including pre- examination, examination, or post-examination processes. Nonconforming examinations or activities occur in many different areas and can be identified in many ways, including clinician complaints, internal quality control indications, instrument calibrations, checking of consumable materials, inter-laboratory comparisons, personnel comments, reporting and certificate checking, laboratory management reviews, and internal and external audits.		
Are nonconforming work and nonconformities documented as required below:		
a. Investigation and determination of the root cause (root cause analysis), and conduct of risk assessment (to determine the level of risk and the need for action);		
Note: Root cause analysis is a process of identifying and removing the underlying factor of the nonconformance.		
 Actions (immediate and corrective) taken to control and/or correct the nonconformity or non-conforming work; 		
Note 1: Are examinations halted and results withheld or recalled where the nonconformity compromises patient results?		
Note 2: Informing the requester where nonconforming work/nonconformity influences the management of the patient.		

ISO15189:2022 Clause 8.7		
10.5 <u>Corrective Action</u> Is corrective action performed and documented for nonconforming work or nonconformities?	Score	/3
ISO15189:2022 Clause 7.5		
10.4 <u>Resumption of Testing</u> Is authorisation for the resumption of testing documented (where testing has been halted)?	Score	/2
10.3 Records of Identification and Management of Nonconforming Work and Nonconformities Are there records of communication to the requester where nonconforming work or a nonconformity influences the management of the patient? ISO15189:2022 Clause 7.5	Score	/2
ISO15189:2022 Clause 7.5 and Clause 8.7	· ·	
 c. Follow up and review of actions to assess effectiveness. Note: Implemented corrective action does not imply effectiveness; therefore, the laboratory must monitor to ensure that the nonconformity has not recurred. 		

SECTION 11: CONTINUAL IMPROVEMENT

For each question, please indicate as relevant, Yes (Y), Partial (P), No (N) or Not Applicable (NA). All elements of the question must be satisfactorily present to indicate Yes (Y). Provide comments for each Partial (P), No (N) or Not Applicable (NA). In the comment field you may also provide information on what was audited i.e., make reference to documentation, equipment, personnel, etc. Y/P/N/ REQUIREMENTS Comment NA 11.1 Procedure and/or Process for Continual /3 Score Improvement Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? Note: Improvement activities must be identified within the preexamination, examination, and post-examination processes. Laboratory management shall ensure that the laboratory participates in continual improvement activities that encompass relevant areas and outcomes of patient care and results records. Identification of improvement activities within the a. laboratory management system; b. Development and documentation of improvement plans; c. Communication of improvement plans and related goals to relevant personnel; Implementation of action plans; d. Recording of improvement plans; e. f. Evaluation of effectiveness of actions taken. ISO15189:2022 Clause 8.6.1 and Clause 8.5 Implementation of Continual Improvement of 12 11.2 Score Management System Does the laboratory identify and undertake continual quality improvement activities? Note: The laboratory should use its management review activities to continually improve its laboratory management system by comparing its actual performance to its intentions stated in the quality policy and objectives. ISO15189:2022 Clause 8.6 11.3 Communication of Continual Improvement Score 12 **Activities** Are the outcomes of continual improvement activities communicated to laboratory management, personnel, and users? Note 1: The communication can be done using graphical tools (such as charts, graphs, tables) and in personnel and management meetings. Note 2: Examples of graphical tools commonly used for this purpose include LJ charts, Pareto charts, cause-and-effect diagrams, frequency histograms, trend graphs, and flow charts. ISO15189:2022 Clause 8.6 SECTION 11: CONTINUAL IMPROVEMENT /07

SECTION 12: FACILITIES AND		
For each question, please indicate as relevant, Yes (Y), Partial (P), No (N satisfactorily present to indicate Yes (Y). Provide comments for each Pa may also provide information on what was audited i.e., make reference to	rtial (P), No	(N) or Not Applicable (NA). In the comment field you
REQUIREMENTS	Y/P/N/ NA	Comment
12.1 <u>Procedure and/or Process for Laboratory Safety</u> Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following? <i>Note 1: The safety procedures and or processes can be in the form</i>		Score /3
of a safety manual. Note 2: Laboratory management must implement a safe laboratory environment in compliance with good laboratory practice and applicable requirements.		
 Ensure all safety measures are implemented at the laboratory as applicable to national and/or international guidelines and regulations. 		
ISO15190:2020 Clause 12.10	-	_
12.2 Facilities and Environmental Conditions (including POCT) Has the laboratory defined a procedure and/or process that addresses, but is not limited to, the following?		Score /3
Note. Evaluating and determining the sufficiency and adequacy of space may be done during internal audits, risk assessments or at management review meetings. However, it must be documented that it was evaluated and found to be adequate.		
 Define how to evaluate and determine the sufficiency and adequacy of the space allocated for the performance of the scope of work; 		
 Ensure storage and disposal facilities meet applicable requirements; 		
 Ensure personnel have space for personal activities (supply of drinking water, storage space for personal and protective equipment and clothing); 		
 Monitor, control and record any specific environmental and facility requirements; 		
e. Sample collection facilities, taking into consideration patient privacy, comfort, and needs (e.g., disabled access, toilet facility) of patients and accommodation of accompanying persons (e.g., guardian or interpreter) during collection;		
 Implementation, recording, monitoring, and reviewing of facility controls (access, safety, etc.). 		
ISO15189:2022 Clause 6.3		
12.3 <u>Adequacy of Size and Layout of Laboratory</u> Is there documented evidence that the laboratory has evaluated the adequacy of the size and layout of the laboratory and organised the space so that workstations are positioned to reduce risk, ensure optimal workflow, and prioritise occupational health?		Score /2
Note: Documentation could be in the form of a floor plan, results from internal audits, risk assessment. Chairs/stools at the workstations should be appropriate for bench height and for the testing operations being performed. ISO15190:2020 Clause 4.2 and Clause 12		

42.4 Detient Core Areas	Secre (2)
12.4 <u>Patient Care Areas</u>	Score /2
Are patient care and testing areas of the laboratory	
distinctly separate from one another?	
Note: Patient care areas (i.e., waiting room, phlebotomy room)	
should be distinctly separate from the testing areas of the	
laboratory. For biosafety reasons, microbiology tuberculosis, and	
molecular testing should be segregated in a separate room(s) from	
the general laboratory testing.	
ISO15189:2022 Clause 6.3.1	
12.5 <u>Housekeeping</u>	Score /2
Are housekeeping activities performed to ensure the	
efficient operations of the laboratory and the safety of the	
personnel, users, and patients?	
a. Are there records of housekeeping duties performed	
daily (at the minimum)?	
b. Are all necessary housekeeping supplies present and	
easily accessible?	
c. Are all equipment and work surfaces (that are used for	
processing contaminated materials) cleaned and	
disinfected with appropriate agents both before and at	
the end of each working shift and whenever spills or	
other contamination has occurred?	
ISO15190:2020 Clause 18	
12.6 Physical Work Environment	Score /3
Is the physical work environment appropriate for testing?	
a. Free of clutter?	
ISO 15190: 2020 Clause 18 j	
b. Adequately ventilated? ISO 15190: 2020 Clause 9.2	
c. Climate-controlled for optimum equipment function?	
ISO 15189:2022 Clause: 6.3.1	
d. Are filters checked, cleaned and/or replaced at regular	
intervals, where air-conditioning is installed?	
e. Are wires and cables properly installed and protected	
from hazardous factors and from traffic?	
f. Is there a functioning back-up power supply	
(generator) and are there records of maintenance?	
g. Is critical equipment supported by uninterrupted power	
source systems?	
h. Is all equipment placed appropriately (away from	
water hazards, out of traffic areas)?	
i. Are appropriate provisions made for adequate water	
supply, including deionised water or distilled water, if	
needed?	
j. Is clerical work performed in a designated clean area?	
k. Is safety signage posted and enforced, including "NO EATING, SMOKING OR DRINKING"?	
ISO15190:2020 Clause 4.2	
12.7 Laboratory Access	Score /2
Is the laboratory properly secured from unauthorised	
access with appropriate systems and signage?	
access with appropriate systems and signage:	
Note: Access control should take into consideration safety,	
confidentiality and quality and safeguard medical information and	
patient samples.	
ISO15190:2020 Clause 4.3.3; ISO15189:2022 Clause 6.3.1	
12.8 Laboratory Storage Areas	Score /3
Is there adequate storage space under the appropriate	
conditions and properly labelled for the following?	
Note: There should be effective separation to prevent contamination.	
contamination.	1

a. Samples;	
b. Equipment;	
c. Reagents and consumables;	
d. Documents and records;	
e. Patient samples and materials used in examination processes (stored separately);	
 f. Hazardous materials and biological waste appropriate to the classification in context of any statutory or regulatory requirements; g. Personnel items, food, and drinks. 	
ISO15189:2022 Clause 6.3	Score /2
12.9 <u>Laboratory Facilities</u> Note: The work area should be cleaned regularly. An appropriate disinfectant should be used. At a minimum, all bench tops and working surfaces should be disinfected at the beginning and end of every shift. All spills should be contained immediately and decontaminated, as appropriate, and the work surfaces disinfected.	Score /2
a. Are laboratory facilities maintained in a functional and reliable condition (e.g., housekeeping and	
 maintenance, etc.)? b. Does the laboratory have adequate safety facilities and devices, where applicable, and regularly verify their proper functioning (eye wash stations, emergency showers, fire alarms, etc.)? 	
c. Is the work area clean and free of leakage and spills, and are disinfection and decontamination procedures conducted and documented, where appropriate?	
ISO15189:2022 Clause 6.3; ISO 15190:2020 Clause 4.2	
12.10 Safety Cabinet (biosafety cabinet, laboratory hood, etc.)Where a biosafety cabinet is present and required to perform work, are the following conditions met, where appropriate?Note: A biosafety cabinet should be used to prevent aerosol	Score /3
exposure to contagious samples or organisms. For proper functioning and full protection, biosafety cabinets require periodic maintenance and should be serviced accordingly. Biosafety cabinets should be recertified according to national protocols or manufacturer requirements.	
 Selection, location, design, and type of biological safety cabinet utilised appropriate to the level of risk containment required for safe working; 	
 Used in such a manner as to avoid compromising the cabinet's function (e.g., jarring or mishandling delicate HEPA filters); 	
 Appropriately vented to the microbiological risk and consistent with safety requirements and frequently monitored to ensure that they function as designed; 	
d. Tested/certified upon installation, when moved or repaired annually by keeping records of the inspection and any functionality testing result;	
e. Proof of inspection indicated by a certification label displayed on the cabinet.	
ISO15190:2020 Clause 7.7.	
12.11 <u>Safety Programme</u> Does the laboratory have a safety programme that includes, but is not limited to, the following elements?	Score /3
a. Safety and health policy;	

	Vritten work procedures that include safe work practices;			
с. Е	Education and training of laboratory-associated			
-	Supervision of personnel;			
e. R	Regular inspections;			
f. ⊢	lazardous materials and substances;			
g. ⊢	lealth surveillance and prophylaxis;			
h. F	irst aid services and equipment;			
i. Ir	nvestigation of accidents and illnesses;			
j. R	Records and statistics;			
	Requirement for follow-up to ensure that all required actions arising from the audit are completed;			
l. F	Fire safety;			
m. C	Oversight of good housekeeping practices.			
ISO 1	5190:2020 Clause 5.7 and Clause 18			
ls a l	2 <u>Laboratory Safety Manual</u> aboratory safety manual available, accessible, and date?		Score	/3
follov	s the safety manual include guidelines on the wing topics?			
a. S	Safety policy;			
b. B	Blood and body fluid precautions;			
c. B	Biosafety and biosecurity hazards, where appropriate;			
d. R	Risk assessment and mitigation;			
e. B	Biological hazards;			
f. ⊢	lazardous waste disposal;			
g. C	Chemical safety;			
h. R	Radiation;			
i. V	/accination;			
	Post-exposure prophylaxis			
	Fire prevention;			
	Electrical safety.			
	•			
	5190:2020 Clause 5.6			12
12.1	3 <u>Waste Disposal</u>		Score	/2
with in conta that d Sharp resist shoul expos	1: Waste should be separated according to biohazard risk, infectious and non-infectious waste disposed of in separate biners. Infectious waste should be discarded into containers to not leak and are clearly marked with a biohazard symbol. to instruments and needles should be discarded in puncture tant containers. Both infectious waste and sharps containers to be autoclaved before being discarded to prevent injury from sed waste; infectious waste should be incinerated, burnt in a r buried.			
capat disca Sharp poten comn	2: All syringes, needles, lancets, or other bloodletting devices ble of transmitting infection must be used only once and rded in puncture resistant containers that are not overfilled. os containers should be clearly marked to warn handlers of the tital hazard and should be available in areas where sharps are nonly used.			
	Is sufficient waste disposal available and adequate?			
,	Is waste separated into infectious and non-infectious waste, with infectious waste autoclaved/incinerated?			
	Are 'sharps' handled and disposed of properly in 'sharps' containers that are appropriately utilised?			

d. Are adequate records of hazardous waste disposal	
retained in an accessible file by the laboratory?	
	Coore /2
12.14 <u>Hazardous Chemicals</u> Are hazardous chemicals/materials properly handled?	Score /3
Note: Chemicals present a broad range of physical (e.g., flammable, corrosive) and biological (e.g., toxic, radioactive, carcinogenic)	
 hazards. a. Are hazardous chemicals properly classified and labelled? 	
 Are chemicals segregated and stored by reactivity class and flammability? 	
c. Are hazardous chemicals properly utilised according to safety data sheets (SDS)?	
Note: The SDS may be available in a computerised format as long personnel are trained on how to access them, the computers are kept in working order and the employer can provide a hard copy of the SDS on request.	
d. Are hazardous chemicals properly disposed of according to national and/or international guidelines or SDS?	
 Is there documented information and records of communication with laboratory personnel regarding the potential routes of entry for toxic chemicals and how best to perform the necessary precautions to 	
prevent exposure?	
 Are oxidizing materials used with appropriate precautions? 	
 Are corrosive materials used with appropriate precautions? 	
 Are suitable chemical spill measures provided, including neutralizing agents, spill containment, and absorbents appropriate for the chemicals used. 	
Note: All hazardous chemicals must be labelled with the chemical's name and with hazard markings. Flammable chemicals must be stored out of sunlight and below their flashpoint, preferably in a steel cabinet in a well-ventilated area. Flammable and corrosive agents should be separated from one another. Distinct care should always be taken when handling hazardous chemicals.	
ISO15190:2020 Clause 8	
12.15 Fire Safety	Score /2
a. Are all electrical cords, plugs, and receptacles used appropriately, installed, and in good condition?	
Note: Overloading should be avoided, and cords should be kept out of traffic areas	
b. Is an appropriate fire extinguisher available, properly placed, in working condition, and routinely inspected?	
Note 1: An approved fire extinguisher should be easily accessible within the laboratory and be routinely inspected and documented for readiness.	
Note 2: Fire extinguishers should be kept in their assigned place and not hidden or blocked, the pin and seal should be intact, nozzles should be free of blockage, pressure gauges should show adequate pressure, and there should be no visible signs of damage.	
c. Are there automatic smoke-detection, heat-detection, and alarm systems adequately placed within the laboratory?	
Note: A fire alarm should be installed in the laboratory and tested regularly for readiness.	

Are safety inspections or audits conducted regularly and documented?		
to all laboratory workers and personnel who share the building? Note: All personnel should participate in periodic fire drills. Fire safety training should be performed during orientation and annually at a minimum. ISO15102020 Clause 11 ISO15102020 Clause 10.2 Note: Work sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspection sor safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? d. Is root cause analysis and corrective action taken for safety inspection findings? e. Are safety inspection findings documented and presented to the laboratory? Isotandard safety equipment available and properly used within the laboratory? Note: Mangement is responsible for providing appropriate personnel protective equipment within the laboratory. Froncetion from series personal protective equipment with the laboratory. Froncetive exploration within the laboratory. Froncetive exploration within the laboratory. Froncetive exploration within the laboratory. Froncetive exploratin within the laboratory. Froncetive exploration with the		
building? Note: All personnel should participate in periodic fire drifts. Fire safety raining should be performed during orientation and annually at a minimum. Storistio:2020 Clause 11 12.16 Safety Audits Are safety inspections or audits conducted regularly and documented? Note: Note sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? d. Is torier a safety audit plan or schedule and properity and presented to the laboratory management and relevant personnel for nerview? Storier active analysis and corrective action taken for safety inspection findings? e. Are safety diright and properity used within the laboratory? b. Storier active action findings documented and presented to the laboratory management and relevant personal rotective equipment with in the laboratory. Frotective control, for providing appropriate personal protective equipment with in the laboratory. Frotective control, and the storatory personal protective equipment with in the laboratory. Frotective control with the laboratory hoods, etc.); So 15190:2020 Clause 1.7 D. Covers, safety case, safety buckets on centrifuge(s); c. Hand-washing station; So 15199:2020 Clause 10.3 So 15199:20		
Note: All personnel should participate in periodic fire drills. Fire safety training should be performed during orientation and annually ISO15190.2020 Clause 11 ISO15190.2020 Clause 11 ISO15190.2020 Clause 11 Score // ISO15190.2020 Clause 11 ISO15190.2020 Clause 12 Score // ISO15190.2020 Clause 12 ISO15190.2020 Clause 12 Score // ISO15190.2020 Clause 2.7 ISO15190.2020 Clause 5.7 Score / ISO15190.2020 Clause 5.7 ISO15190.2020 Clause 5.7		
safety training should be performed during orientation and annually ISO15190.2020 Clause 11 12.16 Safety Audits Score Are safety inspections or audits conducted regularly and documented? Score Note: Work sites shall be surveyed/inspected at least annually. . a. Is there a safety audit plan or schedule that ensures all activities of the faboratory are checked for safety compliance? . b. Are safety inspections or safety audits being carried out by authorised personnel? . c. Are the personnel conducting the internal audits trained in safety? . d. Is root cause analysis and corrective action taken for safety inspection findings? . e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? . Iso15190:2020 Clause 5.7 . 12.17 Safety Equipment svaliable and property used within the laboratory? . Note: Maragement is responsible for providing appropriate personal protective equipment gloves, lab coats, eye protection, etc. /: useable condition. Laboratory personnel must always utilise (abding should not be worn outside designated working areas. . a. Safety cabinet(s) (ncluding biosafety cabinets, laboratory hoods, etc.); . . SO 15190:2020 Clause 7.7 . . C. Hand-washing station; . .	building?	
ISO15190:2020 Clause 11 12.16 Safety Audits Are safety inspections or audits conducted regularly and documented? Note: Work sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? d. Is root cause analysis and corrective action taken for safety inspection findings documented and presented to the laboratory management and relevant personnel for review? ISO15190:2020 Clause 5.7 12.17 Safety Equipment available and properly used within the laboratory? Isolatory prosented personnel control wills in the laboratory? Protective continue audits designade working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory prosonale working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory prosonale working areas. b. Covers, safety caps, safety buckets on centrifuge(s); c. Hard-washing station; SO 15190:2020 Clause 1.2 SO 15190:2020 Clause 1.3 c. Split kit(s); SO 15190:2020 Clause 1.4 So 15190:2020 Clause 1.5 f. First aid kit(s). SO 15190:2020 Clause 1.6 SO 15190:2020 Clause 1.6	safety training should be performed during orientation and annually	
12.16 Safety Audits Score / Are safety inspections or audits conducted regularly and documented? Score / Note: Work sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? c. Are the personnel conducting the internal audits trained in safety? c. Are the personnel conducting the internal audits trained in safety? c. Are safety inspection findings? e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? score / ISO15100.202 Clause 5.7 ISO15100.202 Clause 5.7 Score / Is standard safety equipment envilon the laboratory. Protective equipment separate personal protective equipment glows, lab coats, eye protection, etc.); Score / SO 15100.202 Clause 7.7 b. Covers, safety cabinet(s) (including biosafety cabinet(s); c. Hard-washing station; Score / SO 15100.202 Clause 10.3 Go 15100.202 Clause 10.3 Score / Score / SO 15100.202 Clause 10.3 Score Score Score / / SO 15100.202 Cla		
Are safety inspections or audits conducted regularly and documented? Note: Work sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? Image: Compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? Image: Compliance? c. Are the personnel conducting the internal audits trained in safety? Image: Compliance? d. Is root cause analysis and corrective action taken for safety inspection findings? Image: Compliance? e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? Image: Compliance? Stot150:2202 Clause 5.7 Image: Compliance? Image: Compliance? Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, ere protection, personal protective equipment while in the laboratory? Score Image: Compliance? Statig should not be worn outside designated working areas. a. Safety cashnet(s) (including biosafety cabinets, laboratory hoods, etc.); Statign: Compliance? Image: Compliance? Statign: Compliance with in the laboratory. Image: Compliance? Image: Compliance? Image: Compliance? Note: Management is responsible for providing appropriate personal protective equipment (gloves, laborator) concertitise compliance? Image: Compliance?		0
documented? Note: Work sites shall be surveyed/inspected at least annually. a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? d. Is root cause analysis and corrective action taken for safety inspection findings? e. Are safety suppection findings documented and presented to the laboratory management and relevant personnel for review? ISO15190:2202 Clause 5.7 12.17 Safety Equipment Is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment while in the laboratory. Protection, etc.) in useable condition. Laboratory personiel must always utilise personal protective equipment while in the laboratory. Protective explanated working areas. a. Safety caps, safety buckets on centrifuge(s); C. c. Hand-washing station; So 15190:2202 Clause 1.2 SO 15190:2202 Clause 1.0.3 E. s. Split kit(s); So 15190:2202 Clause 10.2 SO 15190:2202 Clause 10.2 E. So 15190:2202 Clause 10.2 So 15190:2202 Clause 10.2 So 15190:2202 Clause 10.2 So 15190:2202 Clause 10.2 IS Split Kit(s); So 15190:22		Score /2
a. Is there a safety audit plan or schedule that ensures all activities of the laboratory are checked for safety compliance? b. Are safety inspections or safety audits being carried out by authorised personnel? c. Are the personnel conducting the internal audits trained in safety? d. Is root cause analysis and corrective action taken for safety inspection findings? e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? ISO15190:2020 Clause 5.7 12.17 Safety Equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment while in the laboratory. Protective clothing social not be own outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety clause 7.7 co 1519:0:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 1519:0:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.2 IS 1519:0:2020 Clause 10.2 IS 1519:0:2020 Clause 10.2		
at activities of the laboratory are checked for safety compliance? . b. Are safety inspections or safety audits being carried out by authorised personnel? . c. Are the personnel conducting the internal audits trained in safety? . d. Is root cause analysis and corrective action taken for safety inspection findings? . e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? . ISO15190-2020 Clause 5.7 . 12.17 Safety Equipment is responsible for providing appropriate personal protective equipment (gloves, lab costs, ep protection, etc.), in usable condition. Laboratory monitorial must always utilise protective equipment (gloves, lab costs, ep crotection, etc.), in usable condition. Laborator personal must always utilise protective equipment (gloves, lab costs, ep crotection, etc.), in usable condition. Laborator personal must always utilise protective equipment (gloves, lab costs, etc.); . S0 15190-2020 Clause 7.7 . . b. Covers, safety caps, safety buckets on centrifuge(s); . . c. Hand-washing station; . . S0 15190-2020 Clause 4.2 . . d. Eyewash station/bottle(s) and emergency showers where applicable; . . S0 15190-2020 Clause 10.3 . . . S0 15190-2020 Clause 10.2 . <	Note: Work sites shall be surveyed/inspected at least annually.	
out by authorised personnel? C. Are the personnel conducting the internal audits trained in safety? Is root cause analysis and corrective action taken for safety inspection findings? d. Is root cause analysis and corrective action taken for safety inspection findings documented and presented to the laboratory management and relevant personnel for review? Is standard safety equipment Is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personnel may. Protective cloting should not be worn outside designated working areas. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); So tstipo:2020 Clause 1.7 D. Covers, safety caps, safety buckets on centrifuge(s); C. Hand-washing station; Sol 15190:2020 Clause 1.0.5 So 15190:2020 Clause 10.5 First aid kit(s); So 15190:2020 Clause 10.2 So 15190:2020 Clause 10.2 Is 50 15190:2020 Clause 10.2 Is 50 15190:2020 Clause 10.2	all activities of the laboratory are checked for safety	
trained in safety? d. Is root cause analysis and corrective action taken for safety inspection findings? e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? ISO15190:2020 Clause 5.7 12.17 Safety Equipment Is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment (gives, lab coats, eye protection, etc.) in useable condition. Laborator prosonnel must always utilise personal protective equipment will in the laboratory. Protective clothing should not be worn sutside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory broketive caps, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 1.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 15 12.18 Personnel Protective Equipment easily accessible at the workstation and utilised appropriately and consistently?		
safety inspection findings? e. Are safety inspection findings documented and presented to the laboratory management and relevant personnel for review? ISO15190:2020 Clause 5.7 12.17 Safety Equipment is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment will in the laboratory. Protection, etc.) in useable condition. Laboratory personnel must always utilise personal protective equipment wills in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory brooks, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 1.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 15 12.18 Personnel 10.2 ISO 15190:2020 Clause 15 12.18 Personnel 10.2 Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
presented to the laboratory management and relevant personnel for review? Image: Constraint of the laboratory management and relevant personal for review? ISO15190.2020 Clause 5.7 Score 12.17 Safety Equipment Is standard safety equipment available and properly used within the laboratory? Score Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personnel must always utilise personal protective equipment while in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); So SO 15190-2020 Clause 7.7 D b. Covers, safety caps, safety buckets on centrifuge(s); C c. Hand-washing station; So SO 15190-2020 Clause 4.2 So d. Eyewash station/bottle(s) and emergency showers where applicable; So SO 15190-2020 Clause 10.3 So e. Spill kit(s); So SO 15190-2020 Clause 10.5 So f. First aid kit(s). So SO 15190-2020 Clause 10.2 Score ISO15190-2020 Clause 15 Score 12.18 Personnel Protective Equipment spersonal protective equipment easily accessible at the workstation and utilised appropriately and consistently? <td></td> <td></td>		
ISO15190:2020 Clause 5.7 12.17 Safety Equipment Is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personal must always utilise personal protective equipment while in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 Es Of 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 15 ISO15190:2020 Clause 15	presented to the laboratory management and relevant	
12.17 Safety Equipment Score // Is standard safety equipment available and properly used within the laboratory? Score // Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personnel must always utilise personal protective equipment while in the laboratory. Protective could not be worn outside designated working areas. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 D Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; Sovers Sovers SO 15190:2020 Clause 4.2 I I Sovers Sovers d. Eyewash station/bottle(s) and emergency showers where applicable; Sovers Sovers Sovers Sovers SO 15190:2020 Clause 10.3 I Sovers Sovers </td <td></td> <td></td>		
Is standard safety equipment available and properly used within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, eye protection, etc.) in useble condition. Laboratory personnel must always utilise personal protective equipment while in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 15 12.18 Personnal Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
within the laboratory? Note: Management is responsible for providing appropriate personal protective equipment (gloves, lab coats, eye protection, tet:) in useable condition. Laboratory personnel must always utilise personal protective equipment while in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 12.18 Personal protective Equipment expressible at the workstation and utilised appropriately and consistently?		Score /3
personal protective equipment (gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personnal must always utilise personal protective equipment while in the laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory. Protective clothing should not be worn outside designated working areas. a. Safety cabinet(s) (including biosafety cabinets, laboratory hoods, etc.); SO 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 4.5 f. First aid kit(s). Score		
Iaboratory hoods, etc.); Iso 15190:2020 Clause 7.7 b. Covers, safety caps, safety buckets on centrifuge(s); Iso 15190:2020 Clause 4.2 c. Hand-washing station; Iso 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; Iso 15190:2020 Clause 10.3 e. Spill kit(s); Iso 15190:2020 Clause 10.5 f. First aid kit(s). Iso 15190:2020 Clause 10.2 ISO 15190:2020 Clause 10.2 Iso 15190:2020 Clause 15 Iso personal protective equipment easily accessible at the workstation and utilised appropriately and consistently? Score	personal protective equipment (gloves, lab coats, eye protection, etc.) in useable condition. Laboratory personnel must always utilise personal protective equipment while in the laboratory. Protective	
b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2 d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 12.18 Personnel Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
b. Covers, safety caps, safety buckets on centrifuge(s); c. Hand-washing station; SO 15190:2020 Clause 4.2	ISO 15190:2020 Clause 7.7	
c. Hand-washing station;		
d. Eyewash station/bottle(s) and emergency showers where applicable; SO 15190:2020 Clause 10.3 e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 Is personal protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
where applicable; ISO 15190:2020 Clause 10.3 e. Spill kit(s); ISO 15190:2020 Clause 10.5 f. First aid kit(s). ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 12.18 Personnel Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?	ISO 15190:2020 Clause 4.2	
e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). ISO 15190:2020 Clause 10.2 ISO15190:2020 Clause 15 12.18 Personal Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
e. Spill kit(s); SO 15190:2020 Clause 10.5 f. First aid kit(s). SO 15190:2020 Clause 10.2 ISO15190:2020 Clause 15 12.18 Personal Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?	ISO 15190:2020 Clause 10.3	
ISO 15190:2020 Clause 10.5 f. First aid kit(s). ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 12.18 Personal Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
f. First aid kit(s). ISO 15190:2020 Clause 10.2 ISO15190:2020 Clause 15 12.18 Personnel Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?	· · · · · · · · · · · · · · · · · · ·	
ISO 15190:2020 Clause 10.2 ISO 15190:2020 Clause 15 I2.18 Personnel Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?		
ISO15190:2020 Clause 15 12.18 Personnel Protective Equipment Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently? Score	t. First aid kit(s).	
12.18 Personnel Protective Equipment Score Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently? Score	ISO 15190:2020 Clause 10.2	
Is personal protective equipment easily accessible at the workstation and utilised appropriately and consistently?	ISO15190:2020 Clause 15	
workstation and utilised appropriately and consistently?		Score /2
ISO15190:2020 Clause 15		
	ISO15190:2020 Clause 15	

12.19 <u>Personnel Vaccinations</u> Are post-exposure prophylaxis policies and procedures	Score //
readily available to laboratory personnel and implemented after possible and known exposures?	
Note 1: The laboratory must have a procedure for follow-up of possible and known percutaneous, mucus membrane or abraded skin exposure to HIV, hepatitis B virus, hepatitis C virus,	
tuberculosis bacteria, and other applicable pathogens. The procedure should include clinical and serological evaluation and appropriate prophylaxis.	
Note 2: Laboratory personnel should be offered appropriate vaccinations—particularly for hepatitis B virus. Personnel may decline to receive the vaccination. In that situation, personnel must sign a declination form which must be filed in their respective personnel file	
ISO15190:2020 Annex I	
12.20 Post-Exposure Prophylaxis	Score //
Are adverse incidents, accidents, or injuries (from	
equipment, reagents, consumables, occupational injuries,	
medical screening, or illnesses, etc.) fully investigated,	
documented, and subsequent steps taken to reduce the	
possibility of recurrence?	
Note: The laboratory must have a procedure for follow-up of	
possible and known percutaneous, mucus membrane or abraded skin exposure to HIV, hepatitis B virus, or hepatitis C virus. The	
procedure should include clinical and serological evaluation and	
appropriate prophylaxis.	
ISO15190:2020 Clause 7.1.2	
12.21 Management of Adverse Incidents or Injury	Score //
Are adverse incidents or injuries from equipment,	
reagents, occupational injuries, medical screening, or illnesses, documented and investigated?	
innesses, documented and investigated?	
Note: All occupational injuries or illnesses should be thoroughly	
investigated and documented in the safety log or occurrence log, depending on the laboratory. Corrective actions taken by the	
laboratory in response to an accident or injury must also be	
documented.	
ISO15189:2022 Clause 5.3.1.6 and 5.3.2.6; ISO15190:2020 Clause 19.1	
12.22 <u>Safety Training</u>	Score //
Are all personnel (including drivers / couriers,	
phlebotomists and cleaners) performing laboratory activities trained in safety practices relevant to their job	
tasks (including general safety, biosafety, and biosecurity,	
where appropriate)?	
Note: All personnel must be trained in prevention or control of the effects of adverse incidents.	
ISO15189:2022 Clause 6.2	
12.23 Laboratory Safety Officer	Score //
Is a trained safety officer designated to implement and	
monitor the safety programme in the laboratory?	
Note: A safety officer should be appointed to implement and	
monitor the safety program, coordinate safety training, and handle all safety issues. This officer should receive safety training.	
ISO15190:2020 Clause 5.5	
12.24 Biosecurity	Score //
Are biosecurity policies, processes, and procedures	
implemented by the laboratory, where appropriate?	
ISO15190:2020 Clause 7	
CECTION 49, EACH ITIES AND SAE	ETV /67

SECTION 12: FACILITIES AND SAFETY

/57

Part III: Summary of Audit Findings

Summary of the Audit Noted Commendations
Noted Commendations
Noted Limitations
Recommendations

References

- [1] ISO 15189:2022, Medial Laboratories Requirement for quality and competence
- [2] ISO 9000:2015, Quality management systems Fundamentals and vocabulary
- [3] ISO 9001:2015, Quality management systems Requirements
- [4] ISO 15190:2020, Medical laboratories Requirements for safety
- [5] ISO 15194:2009, In vitro diagnostic medical devices Measurement of quantities in samples of biological origin Requirements for certified reference materials and the content of supporting documentation
- [6] ISO 15198:2004, Clinical laboratory medicine In vitro diagnostic medical devices Validation of user quality control procedures by the manufacturer
- [7] ISO/IEC 17011:2017, Conformity assessment General Requirements for the competence of proficiency testing providers
- [8] ISO 17034:2016, General requirements for the competence of reference material producers
- [9] ISO/IEC 17043:2023, Conformity assessment General requirements for proficiency testing
- [10] ISO 17511:2020, In vitro diagnostic medical devices Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples
- [11] ISO 18113-1:2022, In vitro diagnostic medical devices Information supplied by the manufacturer (labelling) — Part 1: Terms, definitions and general requirements
- [12] ISO 19011:2018, Guidelines for auditing management systems
- [13] ISO 20658:2023, Requirements for the collection and transport of samples for medical laboratory examinations
- [14] ISO TS 20914:2019, Medical laboratories Practical guide for the estimation of measurement uncertainty
- [15] ISO 22367:2020, Medical laboratories Application of risk management to medical laboratories
- [16] ISO TS 22583:2019, Guidance for supervisors and operators of point-of-care testing equipment
- [17] ISO/IEC 27001:2022, Information security, cybersecurity and privacy protection Information security management systems Requirements
- [18] ISO 35001:2019, Biorisk management for laboratories and other related organisations
- [19] ISO 5725-1:2023, Accuracy (trueness and precision) of measurement methods and results Part 1: General principles and definitions
- [20] ISO 20186-1:2019, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for venous whole blood Part 1: Isolated cellular RN
- [21] ISO 20186-2:2019, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for venous whole blood Part 2: Isolated genomic DNA
- [22] ISO 20186-3:2019, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for venous whole blood Part 3: Isolated circulating cell free DNA from plasma
- [23] ISO 20166-1:2018, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue Part 1: Isolated RNA
- [24] ISO 20166-2:2018, Molecular in vitro diagnostic examinations Specifications for pre- examinations processes for formalin-fixed and paraffin-embedded (FFPE) tissue Part 2: Isolated proteins
- [25] ISO 20166-3:2018, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue Part 3: Isolated DNA
- [26] ISO 20166-4:2021, Molecular in vitro diagnostic examinations Specifications for preexamination processes for formalin-fixed and paraffin-embedded (FFPE) tissue Part 4: In situ detection techniques
- [27] ISO 20184-1:2018, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for frozen tissue Part 1: Isolated RNA
- [28] ISO 20184-2:2018, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for frozen tissue Part 2: Isolated proteins
- [29] ISO 20184-3:2021, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for frozen tissue Part 3: Isolated DNA
- [30] ISO 4307:2021, Molecular in vitro diagnostic examinations Specifications for pre-examination processes for

saliva — Isolated human DNA

- [31] ISO 23118:2021, Molecular in vitro diagnostic examinations Specifications for pre-examination processes in metabolomics in urine, venous blood serum and plasma
- [32] SI Brochure, The International System of Units (SI), BIPM (<u>http://www.bipm.org/en/publications/si-brochure/</u>)
- [33] CASCO QS-CAS-PROC/33, Common elements in ISO/CASCO Standards 2020
- [34] CLSI Planning for Laboratory Operations During a Disaster; Approved Guideline, CLSI document GP36-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014
- [35] Joint BIPM, OIML, ILAC and ISO declaration on metrological traceability, 2011 (http://www.bipm.org/utils/common/pdf/BIPM-OIML-ILAC-ISO_joint_declaration_2011.pdf)
- [36] Joint Commission for Guides in Metrology (JCGM) International vocabulary of metrology Basic and general concepts and associated terms (VIM) 3rd edition
- [37] International Laboratory Accreditation Cooperation (ILAC). <u>https://ilac.org/</u>
- [38] Logical Observation Identifiers Names and Codes (LOINC and Nomenclature for Properties and Units (NPU, NGC) and SNOMED CT (<u>https://loinc.org</u>)
- [39] WHO, WHO Guide for the Stepwise Laboratory Improvement Process Towards Accreditation in the African Region (with checklist), <u>http://www.afro.who.int/en/clusters-a-programmes/hss/blood-safety-Laboratories-a-health-technology/blt-highlights/3859-who-guide-for-the-stepwise-Laboratory-improvement-process-towards-accreditation-in-the-african-region-</u>
- [40] Centers for Disease Control Atlanta Global AIDS Program. (2008). Laboratory Management Framework and Guidelines. Atlanta, GA: Katy Yao, PhD.
- [41] CLSI/NCCLS. A Quality Management System Model for Laboratory Services— Fifth Edition. CLSI/NCCLS document GMS01. Wayne, PA: NCCLS; 2004. <u>www.clsi.org</u>